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ENSURING THAT INJECTION drug users who cannot or will not
stop injecting have access to sterile syringes is an important part of a
comprehensive approach to reducing the transmission of viral and
bacterial infections associated with injection drug use. I Seen purely in
terms of public health science and prevention practice, ensuring syr-
inge access for injection drug users is clearly an appropriate strategy:
both evaluation research and experience in the field show that ade-
quate syringe access produces positive health effects without negative
social side effects.
I. Introduction
Access to sterile syringes through syringe exchange programs
(SEPs) has been associated with decreased rates of needle sharing,
decreased prevalence and incidence of blood borne infections such as
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1. ACADEMY FOR EDUCATIONAL DEVELOPMENT, NEW ATTITUDES AND STRATEGIES: A
COMPREHENSIVE APPROACH TO PREVENTING BLOOD-BORNE INFECTIONS AMONG IDUs (2000),
available at http://www.cdc.gov/HIV/projects/IDU-ta/brochure.htm.
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HIV and hepatitis B and C, and increased rates of entry into drug
treatment among injection drug users (IDUs). There is no evidence
that such programs increase crime, drug use or the number of dis-
carded needles on the street. Pharmacies, syringevending machines,
and deregulating syringe access can further expand sterile syringe cov-
erage to IDUs, thereby increasing the potential to achieve these posi-
tive public health outcomes.
Despite its public health value, however, syringe access has been
politically controversial in the United States. In our political culture,
driven by symbols and perceptions, improved syringe access has been
painted as "soft on drugs," a retreat from zero tolerance that will be
seen as an endorsement of drug use. Polls continue to show that only
a little more than half of respondents support enhanced syringe ac-
cess-a majority, but evidently one that is too narrow or uncommitted
to counterbalance the intense symbolic force of the syringe access is-
sue in policy-making. Syringe access, then, is quite a familiar public
health policy dilemma: science and professional judgment point to an
intervention that is unsettling, if not absolutely unacceptable, to a sig-
nificant part of the United States public and its political leaders.
Syringe access is regulated by state law. The legal regulation of
syringe access varies from state to state but takes one or more of three
forms: syringe prescription laws and regulations; other pharmacy reg-
ulations or miscellaneous statutes imposing a variety of restrictions on
the sale of syringes by pharmacists or others; and drug paraphernalia
laws prohibiting the sale or possession of items intended to be used to
consume illegal drugs. 2 Laws on drug possession also may be applied
in a manner that in practical terms regulate the possession of syringes
and so must also be considered for their possible effects on syringe
access.
3
The primary policy questions have been the legality of'over-the-
counter sales of syringes to IDUs, the legality of syringe possession by
IDUs, and the authority of public health officials or private sector
providers to initiate access interventions. Where clearly legal modes of
syringe access are absent, proponents of health interventions such as
syringe exchange have had to seek the support of legislators, gover-
nors, mayors, and law enforcement officials. Money, too, has been an
2. Lawrence 0. Gostin & Zita Lazzarini, Prevention of HIV/AIDS Among Injection Drug
Users: The Theory and Science of Public Health and Criminal Justice Approaches to Disease Preven-
tion, 46 EMORY L.J. 587, 595 (1997).
3. Scott Burris et al., State Syringe and Drug Possession Laws Potentially Influencing Safe
Syringe Disposal by Injection Drug Users, 42J. Am. PHARM. ASS'N S94 (Supp. 2 2002).
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issue. At the federal level, there has been an ongoing debate for many
years over what, if any, syringe access research or program activities
can be conducted with federal funding. Meanwhile, syringe access
programs have depended on state or local funding, philanthropy, and
the work of volunteers to operate.
This Article updates and significantly expands upon prior legal
analyses of syringe access. In addition to syringe exchange, it also eval-
uates the role of drug possession laws and addresses the important
issue of syringe disposal. Although it will also discuss the science behind
the syringe access issue, its main purpose is to set out where the
United States stands on syringe access law, practice, and public atti-
tudes, and to suggest ways in which policy can be changed. Because
syringe access is politically controversial, we acknowledge our perspec-
tive on the issue: as public health researchers and scholars, we believe
that an assessment of the best available research in this area suggests
that policies easing access to clean needles can reduce disease trans-
mission without producing substantial countervailing harms.
The main focus of this paper is the body of law that regulates
syringe sale, purchase, possession, and disposal in the context of injec-
tion drug use in the United States, the District of Columbia, the Virgin
Islands, and Puerto Rico. Part II describes the emergence of syringe
access as a matter of health policy and practice. Part III is a thorough
review of the law of syringe access. This body of law includes: drug
paraphernalia laws, syringe prescription laws and regulations, phar-
macy regulations and miscellaneous syringe laws, needle exchange
laws and regulations, and drug possession laws. To place this body of
law in context, Part IV summarizes and critically assesses the public
health research on the health effects of syringe access rules and the
collateral effects of policies enhancing syringe access for IDUs. In Part
V, we examine the public opinion poll ressults, and discuss the ethics
and politics of syringe access reform. Finally, Part VI offers our key
recommendations for public policy.
II. Background
Access to injection equipment has been regulated at the state
level for many years. The hypodermic syringe came into common us-
age in the latter half of the nineteenth century, often as a means for
injecting opiates such as morphine and heroin. As rates of opiate ad-
diction began to increase, states responded with legislation making it
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more difficult for drug users to obtain syringes. 4 New York State en-
acted the first such law in 1911. Among other provisions, New York's
law required a written order from a physician before a syringe could
be obtained. Just three years later, Congress passed the Harrison Act,
which marked the beginning of a major federal role in the control of
the narcotics trade. Beginning in 1915, several other states, mostly in
the east, followed New York's lead and enacted their own laws limiting
the availability of syringes. 5
Legislative efforts to restrict access to injection equipment were
not limited to the early part of the past century, however. Another
important flurry of activity occurred in the 1970s with the rapid adop-
tion of state laws criminalizing the possession of certain devices, in-
cluding syringes, used to inject illegal drugs. These so-called "drug
paraphernalia" laws were often patterned after a Model Drug Para-
phernalia Act (MDPA) written by the Drug Enforcement Agency in
1979 at the request of President Carter.6 They were originally in-
tended to provide a means of prosecuting operators of "head
shops"-stores specializing in equipment for drug users. By 1976, it
was estimated that between fifteen and thirty thousand of these stores
were doing an annual three billion dollar business in such items as
cigarette rolling papers, bongs, and freebasing kits. Syringes were not
generally mentioned in the legislative debates or court challenges to
these laws, nor is it even clear that syringes were being sold in head
shops. Debate about the laws usually focused on their breadth and the
danger that innocent sellers of items with both legal and illegal uses
(such as rolling papers or scales) might be prosecuted. 7 In a few
states, the model law was amended to explicitly exclude pharmacists,
but in most states the possibility that pharmacists would be covered
through the laws' reference to needles was apparently not considered.
Until the emergence of HIV, these laws were seen exclusively in the
context of the control of drug abuse.
HIV changed that as transmission through drug injection was rec-
ognized as a serious threat to public health. The first syringe ex-
change program (SEP) was introduced in Amsterdam, the
4. See Gostin & Lazzarini, supra note 2, at 597.
5. Mark Parts, Disease Prevention as Drug Policy: A Historical Perspective on the Case for
Legal Access to Sterile Syringes as a Means of Reducing Drug-Related Harm, 24 FOROHAM URB. L.J.
475, 482-83 (1997).
6. Gostin & Lazzarini, supra note 2, at 614.
7. Laura Ferguson et al., Syringe Exchange in Pennsylvania: A Legal Analysis, 8 TEMP.
POL. & Civ. RTS. L. REv. 41, 48-49 (1998).
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Netherlands, in 1984.8 The program, initiated by a drug user organi-
zation whose name may loosely be translated as the Junkies' Union,
was soon adopted by the Municipal Health Department of Amster-
dam, where it became a fundamental component of HIV prevention
activities among IDUs. In the late 1980s, SEPs were introduced in the
United Kingdom, Australia, Canada, and several other European
countries. Global expansion of SEPs has occurred in both developed
and developing countries, including China, Russia, the Ukraine,
Kyrgyzstan, Nepal, Bangladesh, India, Pakistan, and Colombia. "As of
December 2000, there were at least 46 regions, countries and territo-
ries that reported having at least one [S]EP."9
In the United States, the first SEP was introduced in 1988, in Ta-
coma, Washington, and spread with the help of non-governmental or-
ganizations such as the National AIDS Brigade, the North American
Syringe Exchange Network, and Act-Up. Expert reviews of the science
supported syringe exchange,10 but early commentators generally as-
sumed that syringe exchange was illegal in the United States unless
explicitly authorized by state law." l By 1995, there were at least 60
SEPs operating in 46 cities in 21 states. 12 A review of the legal strate-
gies used to implement these SEPs found that 27 programs in ten ju-
risdictions had been authorized by law or court decision, or were in a
state without a syringe-related law. Thirteen programs were operating
without any change in law, backed by local governments exercising
8. J.A. van den Hoek et al., Risk Reduction Among Intravenous Drug Users in Amsterdam
Under the Influence of AIDS, 79 Am. J. PUB. HEALTH 1355, 1355 (1989).
9. Steffanie A. Strathdee & David Vlahov, The Effectiveness of Needle Exchange Programs:
A Review of the Science and Policy, 1 AIDSCIENCE 1 (2001), at http://aidscience.com/Articles
/aidsciencd013.pdf.
10. See, e.g., PETER LURIE ET AL., THE PUBLIC HEALTH IMPACT OF NEEDLE EXCHANGE
PROGRAMS IN THE UNITED STATES AND ABROAD: SUMMARY, CONCLUSIONS AND RECOMMENDA-
TIONS (1993);JACQUES NORMAND ET AL., PREVENTING HIV TRANSMISSION: THE ROLE OF STER-
ILE SYRINGES AND BLEACH (1995); NATIONAL COMMISSION ON AIDS, THE TWIN EPIDEMICS OF
SUBSTANCE ABUSE AND HIV 10 (1991); OFFICE OF THE SURGEON GENERAL, EVIDENCE-BASED
FINDINGS ON THE EFFICACY OF SYRINGE EXCHANGE PROGRAMS: AN ANALYSIS FROM THE ASSIS-
TANT SECRETARY FOR HEALTH AND SURGEON GENERAL OF THE SCIENTIFIC RESEARCH COM-
PLETED SINCE APRIL 1998 (2000), available at http://www.harmreduction.org/
surgreview.html.
11. See LURIE ET AL., supra note 10; L.O. Gostin, The Interconnected Epidemics of Drug
Dependency and AIDS, 26 HARV. C.R.-C.L. L. REV. 113 (1991); see also Centers for Disease
Control and Prevention, Syringe Exchange Programs-United States, 1994-1995, 44 MORBIDITY
& MORTALITY WKLY. REP. 684 (1995).
12. See Centers for Disease Control and Prevention, supra note 11, at 684.
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their legal authority to protect public health. At least nine SEPs were
operating without any claim to legal authorization.' 3
Although syringe exchange was developing rapidly at the state
level and finding support in several key states, a controversy over fund-
ing SEPs began to dominate the debate at the federal level. In Novem-
ber 1988, a ban on federal funding for SEPs was enacted.1 4 Provisions
stated that the ban on federal funding could be lifted only if the Presi-
dent of the United States or the Surgeon General determined that
SEPs reduced the transmission of HIV infection and did not increase
drug abuse. More restrictive language was inserted into the Compre-
hensive Alcohol Abuse, Drug Abuse, and Mental Health Amendments
Act of 1988, specifying that no funding could be spent "to carry out
any program of distributing sterile needles for the hypodermic injec-
tion of any illegal drug or distributing bleach for the purpose of
cleansing needles for such hypodermic injection." 5 The Ryan White
Comprehensive AIDS Resources Emergency Act of 1990 included sim-
ilar provisions. Later Department of Health and Human Services ap-
propriations acts prohibited funding for SEPs "unless the President of
the United States certifies that such programs are effective in stopping
the spread of HIV and do not encourage the use of illegal drugs." 1 6
The legislative restrictions included a proviso that would allow fund-
ing if it were certified that syringe exchange reduced HIV incidence
without increasing drug abuse. Because there was also an administra-
tive ban on research to evaluate SEPs from 1988 to 1991,1 7 this was the
quintessential Catch-22.
In 1998, Secretary of the Department of Health and Human Ser-
vices, Donna Shalala issued the findings required to lift the ban on
federal funding, but the Clinton administration, in the face of contin-
uing opposition in Congress and from its own Office of National Drug
Control Policy, declined to seek funding for syringe exchange pro-
13. Scott Burris et al., The Legal Strategies Used in Operating Syringe Exchange Programs in
the United States, 86 AM. J. PUB. HEALTH 1161 (1996).
14. See Health Omnibus Programs Extension of 1988, Pub. L. No. 100-607, § 256, 102
Stat. 3048 (codified in 42 U.S.C. § 300ee-5 (2003)).
15. Comprehensive Alcohol Abuse, Drug Abuse, and Mental Health Amendments
Act, Pub. L. No. 100-690, § 2025, 102 Stat. 4193 (1988) (amended 42 U.S.C. § 300x-3; re-
pealed by ADAMHA Reorganization Act, Pub. L. No. 102-321, § 201, 106 Stat. 378).
16. Departments of Labor, Health and Human Services, and Education, and Related
Agencies Appropriations Act, Pub. L. No. 101-166, § 520, 103 Stat. 1159 (1990); see also
Departments of Labor, Health and Human Services, and Education, and Related Agencies
Appropriations Act, Pub. L. No. 101-517, § 513, 104 Stat. 2190 (1991).
17. David Vlahov et al., Needle Exchange Programs for the Prevention of Human Immu-
nodeficiency Virus Infection: Epidemiology and Policy, 154 AM. J. EPIDEMIOLOGY S70, S71 (2001).
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grams or for research. The Surgeon General reiterated the Secretary's
findings in 2000.18 Nevertheless, since 1999 the annual Labor, Health
and Human Services appropriations bills have contained a ban on fed-
eral funding of syringe exchange. 19
For many years there has also been an annual battle over the
Congressional budget appropriation for the District of Columbia. Rid-
ers to the fiscal year 2001 not only prohibited the District from fund-
ing syringe exchange, but also barred a privately funded SEP from
operating close to public housing and within 1000 feet of a school. 21
After vigorous lobbying from proponents of SEPs, the fiscal year 2002
appropriation removed the restrictions on the operation of the pri-
vate SEP, but maintained the ban on federal funding.21
Despite the lack of federal funding, by 1999 there were over 160
SEPs in operation in 39 states, the District of Columbia, and Puerto
Rico. 22 Yet the lack of federal and state support for SEPs has clearly
taken its toll. In a survey of 81 SEPs across the United States, Denise
Paone and colleagues reported that SEPs that operated illegally were
significantly less likely to offer crucial ancillary services, such as on-site
HIV testing and counseling and formal arrangements for referrals to
drug abuse treatment services. 23 In 1993, an evaluation of twelve
North American SEPs reported that these programs seldom reached
18. See OFFICE OF THE SURGEON GENERAL, supra note 10.
19. Departments of Labor, Health and Human Services, and Education, and Related
Agencies Appropriations Act, Pub. L. No. 105-78, § 505, 111 Stat. 1467 (1998); Depart-
ments of Labor, Health and Human Services, and Education, and Related Agencies Appro-
priations Act, Pub. L. No. 105-277, § 505, 112 Stat. 2681 (1999); Departments of Labor,
Health and Human Services, and Education, and Related Agencies Appropriations Act,
Pub. L. No. 106-113, §505, 113 Stat. 1501 (2000); Departments of Labor, Health and
Human Services, and Education, and Related Agencies Appropriations Act, Pub. L. No.
106-554, § 505, 114 Stat. 2763 (2001); Departments of Labor, Health and Human Services,
and Education, and Related Agencies Appropriations Act, Pub. L. No. 107-116, § 505, 115
Stat. 2177 (2002); Departments of Labor, Health and Human Services, and Education, and
Related Agencies Appropriations Act, Pub. L. No. 108-7, § 505, 117 Stat. 11 (2003) (stating,
"[n]otwithstanding any other provision of this Act, no funds appropriated tinder this Act
shall be used to carry out any program of distributing sterile needles or syringes for the
hypodermic injection of any illegal drug").
20. See Department of Commerce, Justice, and State, the Judiciary, and Related Agen-
cies Appropriations Act, FY2001, Pub. L. No..106-553, § 150, 114 Stat. 2762.
21. See District of Columbia Appropriations Act, Pub. L. No. 107-96, § 125, 115 Stat.
923 (2002).
22. P.O. Coffin et al., New York City Pharmacists'Attitudes Toward Sale of Needles/Syringes
to Injection Drug Users Before Implementation of Law Expanding Syringe Access, 77J. URB. HEALTH
781 (2000).
23. Denise Paone et al., Syringe Exchange in the United States, 1996: A National Profile, 89
AM. J. PUB. HEALTH 43, 44-45 (1999).
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more than 30% of the IDUs in their communities. 24 Although SEPs in
the United States distribute some 15-20 million syringes each year,25
it is estimated that America's 1.5 million IDUs annually perform be-
tween 920 million and 1.7 billion injections. 26 In countries like the UK
and Australia, where SEPs are supported both federally and locally,
the number of sterile syringes provided per IDU per year is much
higher. 27
The continuing federal funding controversy coincided with and
may even have contributed to a stall in the authorization of new SEPs
at the state and local levels. In part, however, the decline in legislation
addressing SEPs has reflected the increasing awareness by syringe ac-
cess proponents of the limitations of SEPs and the need for other,
complementary strategies. In recent years, advocates in several states
have successfully sought "syringe deregulation"-the removal of legal
barriers to over-the-counter sales and free distribution of syringes.
Deregulation in its purest form eliminates all significant legal restric-
tions on the sale or possession of hypodermic needles and syringes. It
allows the broadest range of syringe access options for IDUs, includ-
ing SEPs, retail sales, physician prescription and distribution, vending
machine sales, and free distribution through community organiza-
tions and public health agencies. It decriminalizes needle possession,
eliminating criminal law as a deterrent to sterile injection. Less sweep-
ing forms of deregulation allow the sale and possession of a specified
number of syringes, or lift restrictions on sales in pharmacies.
Since the beginning of the HIV epidemic, twelve states (Connect-
icut, Hawaii, Illinois, Maine, Minnesota, New Hampshire, New Mex-
ico, New York, Oregon, Rhode Island, Washington, and Wisconsin)
have deregulated the sale or possession of at least some number of
syringes. In others, notably California, efforts at deregulation have
been unsuccessful. To date, no state that has liberalized syringe access
in response to HIV has rescinded the change, but change continues to
be a controversial matter in states that maintain restrictive access
policies.
24. LURIE ET AL., supra note 10, at 15.
25. See, e.g., Paone et al., supra note 23, at 44; Centers for Disease Control and Preven-
tion, Update: Syringe Exchange Programs-United States, 1998, 50 MORBIDIIY & MORTALITY
WKLY RP. 384, 386 (2001).
26. Parts, supra note 5, at 476-77; P. Lurie et al., A Sterile Syringe for Every Drug User
Injection: How Many Injections Take Place Annually, and How Might Pharmacists Contribute to
Syringe Distribution?, 18 J. ACQUIRED IMMUNE DEFICIENCY SYNDROMES & HUMAN RE-
TROVIROLOGY S45, $46-$47 (Supp. 1 1998).
27. Strathdee & Vlahov, supra note 9.
[Vol. 37
Public health authorities recommend that injection drug users
use a new, sterile syringe for every injection.28 Despite the continued
growth of syringe exchange, and the deregulation of syringes in one-
fifth of the states, the United States has consistently fallen far short of
this public health goal. In the third decade of its HIV epidemic, the
United States continues to debate whether and how to make syringes
available to injection drug users.
III. Syringe Access Policy in the United States: A Summary
of the Law and the Prior Studies
Selling, buying, possessing, and disposing of syringes are heavily
regulated activities. With a few exceptions, the prior studies of syringe
access legality, summarized in Section A below, have focused on the
presence or absence of the various forms of syringe access regulation
in the states. This is an important topic, and Section B below summa-
rizes the latest data on which states have what laws. But syringe access
law is much more complicated than what a simple list of laws can
show. Although many of these laws are generally similar from state to
state, there is in fact a great deal of state-to-state variation in legal
syringe access for IDUs. Moreover, legal researchers have increasingly
recognized that the legality of different means of syringe access de-
pends upon the form of access (e.g., syringe exchange or pharmacy),
the legal status of the person providing the access (e.g., a physician),
the particular combination of laws and case decisions in the state, and
the attitudes of people who enforce the laws where the access provider
wants to operate. This review therefore adds a new analytic step to the
existing literature on syringe access law, by analyzing state-by-state the
legality of three basic modes of syringe access: retail sale without a
prescription, sale with a prescription, and syringe exchange or other
forms of free distribution.
A. Previous Studies of SEP Laws
The legality of syringe access for IDUs in the United States has
been previously explored. Mark Parts' review of the history of syringe
access laws provided an excellent overview of current and past legisla-
tion, as well as a thorough review of largely forgotten medical litera-
ture describing outbreaks of malaria, tetanus, and other needle-borne
28. U.S. PUBLIC HEALTrH SERVICE, HIV PREVENTION BULLETIN: MEDICAL ADVICE FOR PER-
SONS WHO INJECT ILLICIT DRUGS 4 (1997).
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disease among IDUs in the early and mid-twentieth century. 29 Several
articles and reports in the first decade of the AIDS epidemic identi-
fied syringe prescription and drug paraphernalia laws as possible bar-
riers to preventing HIV infection among IDUs.31 1 Some early surveys of
SEPs based their assessment of legality on the presence or absence of
a syringe prescription law, ignoring paraphernalia or pharmacy prac-
tice laws."' When discussed, paraphernalia laws were assumed to pro-
hibit SEPs and retail sale of syringes. 3 2 Gostin and Lazzarini 3
undertook a study of the laws and regulations applicable to syringe
access, including the prescription, drug paraphernalia, and pharmacy
practice rules of all fifty states and United States territories. Although
comprehensive in its scope, the study did not analyze the law on a
state-by-state basis, so meaningful differences in the wording of para-
phernalia, prescription, and pharmacy regulations, and important le-
gal issues of their interaction in a given state, were noted but not
examined.
Burris and colleagues34 used legal research and survey techniques
to identify the legal strategies used by SEPs to operate in the United
States. Their analysis identified considerable uncertainty in the legal
status of syringe exchange, uncertainty that reflected not only the
complexity of the relevant statutes but also the interplay of multiple
statutes and the practices of law enforcement and public health offi-
cials. Uncertainty about the legal status of syringe exchange was con-
siderably different than clear illegality. SEPs, the study found, could
successfully operate without explicit authorization in a climate of un-
certainty. Likewise, absent a clear legal prohibition in state law, local
governments often had the authority under public health laws to op-
erate or authorize SEPs. The legal and practical effects of this uncer-
29. See Parts, supra note 5, at 490-504.
30. Larry 0. Gostin, The Interconnected Epidemics of Drug Dependency and AIDS 26 HARV.
C.R.-C.L. L. REV. 113, 139 (1991); seeJeff Stryker, IV Drug Use and AIDS: Public Policy and
Dirty Needles, 14J. HEALTH POL., POL'Y AND L. 719, 728 (1989); Larry Gostin, Drug-Dependent
Populations: Legal and Policy Options, in AIDS AND IV DRUG ABUSERS 253 (R. Galea et al.,
1988); see Chris Pascal, Intravenous Drug Abuse and AIDS Transmission: Federal and State Laws
Regulating Needle Availability, in NEEDLE SHARING AMONG INTRAVENOUS DRUG ABUSERS: NA-
TIONAL AND INTERNATIONAL PERSPECTIVES 119, 119 (R. Batjes & R. Pickens eds., 1988); see
Catherine O'Neill, Intravenous Drug Abusers, in AIDS AND THE LAw: A GUIDE FOR THE PUBLIC
253, 278-280 (H. Dalton et al., 1987) (describing early reports and recommendations).
31. See Centers for Disease Control and Prevention, supra note 11, at 685; Paone et al.,
supra note 23 at 43-44.
32. See Gostin, supra note 11, at 136-37.
33. See Gostin & Lazzarini, supra note 2.
34. Burris et al., supra note 13, at 1161.
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tainty were illustrated by Ferguson and colleagues,3 5 who analyzed in
detail the law of one state to show that syringe exchange could reason-
ably be considered legal using a conventional legal analysis even
though the state had both a drug paraphernalia law and a syringe
prescription regulation.
The importance of dealing with intra-state legal complexity and
the inherent uncertainty of much legal analysis was the starting point
for Burris and colleagues,3 6 who investigated the legality of physician
prescription and pharmacy sale of syringes to IDUs, a mode of access
first suggested by Gostin and Lazzarini.37 This study used a different
methodology than Gostin and Lazzarini, taking the collected data
and, for each state and territory covered, creating a memorandum an-
alyzing the statutes and case law according to standard legal practices.
These memoranda were also the basis of an analysis of syringe deregu-
lation prepared by Burris and Ng for the AIDS Coordinating Commit-
tee of the American Bar Association.
3 3
Related legal issues have also been studied. Maxwell Mehlman as-
sessed the tort issues associated with syringe access by physician pre-
scription and pharmacy sale, finding that the risk of civil liability for
providing syringes was remote.39 Daniel Abrahamson reviewed the ef-
fect of federal law on syringe access, and concluded it was minimal.
4
"
B. Syringe Access Law Today
This section updates Gostin and Lazzarini's 41 survey of syringe ac-
cess law, accounting for the many changes to the law that have oc-
curred in the past five years. This section also summarizes state laws
that define the minimum amount of drugs it is a crime to possess.
35. Ferguson et al., supra note 7, at 42.
36. See Scott Burris et al., Physician Prescribing of Sterile Injection Equipment to Prevent HIV
Infection: 7imefor Action, 133 ANNALS OF INTERNAL MED. 218, 220 (2000) [hereinafter Burris,
Time for Action]; see Scott Burris et al., Harm Reduction in the Health Care System: The Legality of
Prescribing and Dispensing Syringes to Drug Users, 11 HEALTH MATRIX 5, 19-24 (2001) [herein-
after Burris, Harm Reduction] (These memoranda are available at http://www.temple.edu/
lawschool/aidspolicy.).
37. See, e.g., Gostin & Lazzarini, supra note 2.
38. See generally Scott Burris & Mitzi Ng, Deregulation of Hypodermic Needles and Syringes
as a Public Health Measure: A Report on Emerging Policy and Law in the United States, 12 GEO.
MASON U. Civ. RTS. L.J. 69 (2001).
39. Maxwell J. Mehiman, Liability for Prescribing Intravenous Injection Equipment to IV
Drug Users, 11 HEALTH MATRIX 73, 82 (2001).
40. Daniel Abrahamson, Federal Law and Syringe Prescription and Dispensing, 11 HEALTH
MATRIx 65, 65 (2001).
41. Gostin & Lazzarini, supra note 2.
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1. Prescription Laws
Thirteen states and the Virgin Islands impose some form of syr-
inge prescription requirement by statute. Pennsylvania requires a pre-
scription by pharmacy board regulation, not by statute. The
prescription requirement stands as a substantial barrier to syringe ac-
cess in only six of these jurisdictions: California, Delaware, Massachu-
setts, New Jersey, Pennsylvania, and the Virgin Islands. In Florida and
Virginia, a prescription is required only for minors.42 In Nevada, a
prescription is not required for syringes to be used for asthma, diabe-
tes, or other medical conditions;43 these exceptions, in combination
with a favorable view of syringe sales from the pharmacy board, have
reportedly led to reasonably liberal syringe access in the state. The
remaining five prescription-law states-Connecticut, Illinois, New
Hampshire, New York, and Maine-have partially deregulated syr-
inges and now allow non-prescription sale and possession of syringes
in limited numbers. Illinois, like Florida and Virginia, does not permit
non-prescription sale to minors. These statutes, and any requirements
they may impose in addition to a prescription, are summarized in Ta-
ble I.
2. Other Pharmacy Regulations and Miscellaneous Statutes
Four other types of restriction on the sale of syringes appear in
state law, usually but not always within the Pharmacy Code. Twenty-
two states allow only pharmacies to sell syringes. Nine require the
seller to determine, or the buyer to produce information about, how
the syringe will be used. Fourteen require records of some type to be
kept. Eleven require the buyer to show identification. Finally, twelve
states specify limits on the display of syringes in retail establishments,
normally requiring that they be kept behind the counter. These sub-
prescription limits on syringe sales are most often (but not always)
found in state pharmacy laws and regulations, and are therefore usu-
ally referred to as "pharmacy regulations." Pharmacy regulations were
collected and presented in tabular form by Gostin and Lazzarini in
1997, and we were provided with access to some of their data.44 Phar-
macy regulations are also reported annually in tabular form by the
National Association of Boards of Pharmacy. To update and verify the
information from these sources, we compared pharmacy regulations
42. FLA. STAT. ANN. § 893.147(3) (b) (West 2002); VA. CODE ANN. § 54.1-3468 (Michie
2003).
43. NEV. REV. STAT. ANN. § 454.480(2) (Michie 2001).
44. Gostin & Lazzarini, supra note 2, at 631-637.
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collected by Gostin and Lazzarini with the results of our own collec-
tion of pharmacy regulations from Lexis, Westlaw, and printed copies
of regulations compiled in 1999-2000, and with the 2001 NABP phar-
macy law survey.45 Where there were discrepancies, we rechecked the
regulations on Westlaw or Lexis, and/or contacted regulatory agen-
cies. Results are included in Table I.
3. Drug Paraphernalia Laws
The District of Columbia and every jurisdiction studied except
Alaska and Puerto Rico have drug paraphernalia laws. Most of these
laws were passed in the 1970s and 1980s to regulate an increasing re-
tail trade in drug-use equipment, and closely followed a model para-
phernalia law drafted by the United States Department of Justice. 46
The typical statute defines drug paraphernalia to include all equip-
ment, products, and materials of any kind which are used, intended
for use, or designed for use to "manufacture, inject, ingest, inhale, or
otherwise introduce into the human body a controlled substance" in
violation of law. 47 It then provides an exemplary list of items that
could be considered drug paraphernalia in some intended uses. In
the majority of states, this list includes "[h]ypodermic syringes, need-
les, and other objects used, intended for use, and designed for use in
parenterally injecting controlled substances into the human body."48
Under this definition, the status of any item as paraphernalia depends
not just on the characteristics of the item itself but also on the inten-
tion or acts of the defendant. To commit a crime, the seller must not
only transfer possession of the syringe, but must do so knowing of the
intended drug-related use. 49 Paraphernalia laws usually create two ba-
sic offenses: manufacturing or distributing and possessing parapher-
nalia. Not every state has created both offenses. The crime is typically
a misdemeanor.
Nearly all state paraphernalia laws follow the same pattern,
though there are small but important differences in many states that
influence the applicability of paraphernalia laws to syringes. In addi-
tion to the states, discussed below, that have fully or partially deregu-
lated syringes as a public health measure, a significant minority of
45. NATIONAL ASSOCIATION OF BOARDS OF PHARMACY, 2001-2002 SURVEY OF PHARMACY
LAw (2002).
46. Gostin & Lazzarini, supra note 2, at 615.
47. NEB. REV. STxr. § 28-441(1) (2002).
48. NEB. REV. STAT. § 28-439(3).
49. Commonwealth v. Lacey, 496 A.2d 1256, 1259-1260 (Pa. Super. Ct. 1985).
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states have provisions that, at least on paper, make it legal under some
circumstances for a seller knowingly to dispense a syringe to an IDU.
These exemptions, set out in Table II, take several forms. Ten state
paraphernalia laws explicitly or implicitly exempt the possession of
syringes in at least some quantity. Indiana's statute, for example, ex-
empts items "historically and customarily used in connection with
the.., injecting.., of ... lawful substance [s]," thus, at least in theory,
legalizing over-the-counter pharmacy sales of syringes. 50 In nine states,
pharmacists and in some instances other health care providers are ex-
empt from the law. In four states with laws based on the Justice De-
partment's model act, the drafters of the paraphernalia law chose to
depart from the model and did not refer to injection or syringes in
the text of the law. Although the broad definition of paraphernalia
reasonably could be deemed to include syringes even without explicit
reference, the decision to omit the references while otherwise adopt-
ing the Justice Department model could be read by a judge as evi-
dence of a legislative decision not to prohibit syringe sale and
possession. In a fifth state, South Carolina, the statute was not based
on the model act: it does not allude to injection or syringes, and more
importantly does not apply to items to be used in the consumption of
heroin. 51 In states that have both paraphernalia and prescription laws,
the interaction of the two must be assessed individually.
Paraphernalia laws were broadly written to criminalize sale or
possession of any item intended to be used to facilitate illegal drug
use. In theory, items that are used in drug injection-like cotton and
small vessels used to dissolve drugs ("cookers") and even bleach kits-
are legally indistinguishable from syringes. Because items used in drug
preparation have also been implicated in the spread of blood borne
diseases, especially hepatitis C virus, public health agencies and syr-
inge exchange programs have routinely distributed them along with
syringes. In areas where syringe exchange has not been authorized,
some agencies distribute bleach kits as an alternative harm reduction
measure. With the political focus on syringe access, the potential legal
ambiguity of these other activities was largely ignored. In recent years,
however, there have been anecdotal reports of SEPs being deterred
from offering, and IDUs being arrested for possessing, sterile cookers
and cotton. Efforts to import specially designed sterile cookers that
have been used in other countries' public health efforts have been
affected by concern about the potential application of paraphernalia
50. IND. CODE ANN. § 35-48-4-8.5(d)(2) (2003).
51. S.C. CODE ANN. § 44-53-391(a) (Law. Co-op 2000).
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Table II: Syringe-Related Exemptions in State Drug
Paraphernalia Laws (excludes SEP provisions)
Exempts some or all Exempts some types of Omits reference Other significant exemp-
syringes (10) sellers (9) to syringes or tion (6)
injection (5)
CT (<31) CA (MDs & pharmacists) CO IA (syringes sold for "law-
IN (items customarily used GA (pharmacists) MI ful purpose")
to inject lawful substances) HI (MDs, pharmacists & NV IA (items for medical use)
IL (<21) health care institutions) SC MA (does not criminalize
ME MT (MDs & pharmacists) WY paraphernalia possession)
MN NM (pharmacists) MI (does not criminalize
NH OH (MDs & pharmacists) paraphernalia possession)
NY (syringes legally obtain- TN (MI)s & pharmacists) SC (does not cover items
ed from pharmacy or SEP) WA (pharmacists) used with heroin)
OR WV (licensees such as VA (does not criminalize
RI pharnacists) paraphernalia possession)
WI
laws. The problem does not appear to be widespread, but does illus-
trate the potential scope of drug paraphernalia laws.
4. Deregulation
A number of states have substantially changed their regulation of
syringe access in response to the public health threat of injection-re-
lated diseases. What is often referred to as "deregulation" is the re-
moval of state law as a barrier to syringe access. It has taken a variety of
forms, which are summarized in Table III.
Oregon was the first state to squarely face the question of syringe
access as a public health measure. Prior to 1987, syringe sales were not
regulated. In that year, the state legislature passed a paraphernalia law
based on the model statute, but heeded the advice of state health offi-
cials to explicitly exclude syringes from the definition of parapherna-
lia.52 In Oregon, it is therefore legal to sell needles not only in
pharmacies but also in other retail .outlets, possibly even vending ma-
chines, and to distribute them for free through SEPs or other mecha-
nisms. This approach can be described as "complete deregulation"
and minimizes the legal barriers to syringe access.
Wisconsin followed Oregon's approach in 1989, but the next
state to act adopted a rather different model. Connecticut, which had
been the first state to legislatively authorize an SEP, took on the issue
52. OR. REV. STAT. §§ 475.525(3) (2002); Lester N. Wright & Kristine M. Gebbie, Ore-
gon's Exclusion of Syringes from Its 1987 Drug Paraphernalia Law Was an HIVPrevention Measure,
18 J. ACQUIRED IMMUNE DEFICIENCY SYNDROMES & HUMAN RETROVWROLOCv S144 (Supp. 1
1998).
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of wider retail access in 1992. The legislature elected to allow retail
sale of syringes without a prescription, but only in pharmacies and
only in an amount of ten or fewer.53 At the same time, the parapher-
nalia law was amended to exclude hypodermic syringes and needles
sold or possessed in an amount of ten or fewer. In 1999, the posses-
sion, but not the purchase, limit was raised to thirty.54 The numbers,
and indeed the entire approach, were born of politics rather than
health concerns. 55 The "ten-and-under" approach, in which sale and/
or possession is legalized only in a specified number of syringes, has
been followed by Illinois (twenty and under), Maine, Minnesota, New
Hampshire, and New York.56
The ten-and-under approach appears to cause some confusion or
conflict over the legality of particular syringes. Because the legality of
a syringe depends, in a partial deregulation system, on factors includ-
ing where it was obtained and how many others are in the possessor's
control, some police officers continue to regard a syringe as illegal
unless proven otherwise. In Connecticut, the ambiguous legal status
of needles led to continuing reports from SEPs, IDUs and public
health officials that police officers were continuing to stop drug users
and arrest them for needle possession. The problem eventually came
to federal court. In Doe v. Bridgeport Police Dept.,57 a federal judge pro-
hibited the Bridgeport Police Department from stopping, searching,
arresting, or threatening any person in possession of fewer than thirty-
one sterile or previously used needles.
Unrestricted pharmacy sales-a third variation on deregula-
tion-emerged in 2000-2002 in Rhode Island, New Mexico, Hawaii,
and Washington. The Rhode Island legislature repealed its prescrip-
tion law and eliminated all criminal penalties for syringe possession.
The legislature also amended its paraphernalia law to make clear that
syringes were not covered by removing its reference to "[h]ypodermic
syringes, needles, and other objects intended for use or designed for
use in parenterally injecting controlled substances into the human
53. CONN. GEN. STAT. ANN. § 21a-65 (West 2003).
54. Id. § 2la-240(20).
55. See Sarah Bray, et al., Doffing the Cap: Increasing Syringe Availability by Law but Not in
Practice, 12 INT'LJ. DRUG POL'Y 221, 222 (2001).
56. See 720 ILL. COMP. STAT. ANN. 600/3.5-4, 635/1-2 (West 2003); see also ME. REV.
STAT. ANN. tit. 17-A, § 1110 (West 2003); MINN. STAT. §§ 151.40(2), 325F.785, 145;924
(2002); N.H. Rltv. STAT. ANN. § 318:52-c(I) (c), (2002); N.Y. PUB. HEALTH LAw § 3381.1(c)
(Consol. 2003); N.Y. GEN. Bus. LAw § 853.2 (Consol. 2003) (other than Illinois, these states
specify ten and under).
57. Doe v. Bridgeport Police Dep't, 198 F.R.D. 325, 350 (D. Conn. 2001).
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body."58 This deregulation act requires pharmacists to provide infor-
mation on drug treatment, HIV prevention, and safe disposal prac-
tices to purchasers.
By regulating only sales, Rhode Island provides more options for
public health distribution of needles for free. Thus, the Rhode Island
law effectively legalizes syringe exchange altogether and could allow
other, less formal modes of distribution. 59 (In Rhode Island, syringe
exchange programs were previously allowed under a separate provi-
sion, R.I. Gen. Laws Section 23-11-19, which places the department of
health in charge of operating or supervising the program(s).) It
should be noted that a deregulation law that confined all delivery of
syringes to pharmacies would not liberalize free distribution as Rhode
Island's law has done, because that term usually embraces all transfers,
not just sales. Because it eliminates all criminal penalties for syringe
access, Rhode Island's model, like Oregon's, substantially reduces the
role of law enforcement as a deterrent to sterile injection.
New Mexico's new policy was less sweeping. It exempted from the
paraphernalia law only "the sale or distribution of hypodermic syr-
inges and needles by pharmacists licensed pursuant to the Pharmacy
Act."' 60 Because it mentioned both sale and distribution, the statute
could not reasonably be read to follow Rhode Island in deregulating
free distribution. Passed in haste at the end of the legislative session,
the law did not as clearly as possible decriminalize the possession of
syringes by IDUs, though this appears to have been the intent.
In 2001, the Hawaii legislature passed a temporary act (set to re-
peal in 2004) that allows a physician, pharmacist, or institutional
health care employee acting under the supervision of a physician or
pharmacist to provide sterile hypodermic syringes in a pharmacy, phy-
sician's office, or health care institution for the purpose of preventing
the transmission of dangerous blood-borne diseases. 6' The law also
legalized syringe possession by the IDU. In contrast to Rhode Island,
its language seemed by implication to forbid free distribution.
Washington's legislature passed, in 2002, an amendment to the
state paraphernalia law exempting syringes distributed through phar-
macies (free or for cost) from the paraphernalia law, stating that "[i] t
58. Uniform Controlled Substances Act Amendments, R.I. Pub. L. ch. 520 (2000)
(codified as amended at R.I. GEN. LAws § 21-28-4.04 (2002)).
59. See R.I. GEN. LAws § 23-11-19(a) (2002) (The department of health maintains and
supervises the needle exchange program.).
60. N.M. STAT. ANN. § 30-31-25.1(B)(2) (Michie 2002).
61. 2001 Haw. Sess. Laws, Act 292, § 1 (West 2001).
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is lawful for any person over the age of eighteen to posses sterile hypo-
dermic syringes and needles for the purpose of reducing blood borne
diseases;" it also specified, however, that no pharmacist is required to
sell syringes. 62 A section of the bill mandating the provision of materi-
als about drug treatment and proper syringe disposal, and setting
other limits on pharmacy sales, was vetoed by the Governor. 63
5. Drug Possession Laws
Although they are not directed explicitly at syringes, drug posses-
sion statutes are also relevant to syringe access. In all but six jurisdic-
tions, controlled substance possession laws embrace or could be
interpreted to embrace any measurable amount of drug.64 See Table
IV. This means that the amount of drug left in the barrel of a syringe
after use could be sufficient to ground a conviction for drug posses-
sion. This in turn means that a used syringe possessed under circum-
stances indicative of drug use can legally justify arrest and "search" for
drugs both in the syringe and on the person of the possessor. There
are reports that IDUs have been prosecuted under these circum-
stances and that fear of such prosecutions acts in practical terms to
regulate the possession of the syringe itself.65
The prosecution of IDUs for possession of controlled substances
based on the residue of drugs left in a used syringe was challenged in
lawsuits in Connecticut and New York. The plaintiffs, who were clients
of legal SEPs and (in Connecticut) legal pharmacy purchasers, suc-
cessfully argued that such prosecutions were illegal under the state
laws that had liberalized syringe access. 66 In Connecticut, the federal
court held that Connecticut's syringe exchange and pharmacy-sale
laws had not only eliminated criminal penalties for possessing fewer
than 31 needles, but also necessarily decriminalized possession of any
trace amounts of drug in the used syringe. The court reasoned that
[c]riminalizing the possession of trace amounts of narcotics within
decriminalized, previously-used hypodermic syringes and needles
would lead to absurd results which would thwart the public-health
62. See 2002 Wash. Legis. Serv. 213 (West) (codified in WASH. REV. CODE ANN.
§§ 69.50.4121(3), 69.50.412(5), 70.115.060 (West 2003)).
63. See 2002 Wash. Legis. Serv. 213 (West).
64. See Danny R. Veilleux, Minimum Quantity of Drug Required to Support Claim that De-
fendant Is Guilty of Criminal Possession of Drug under State Law, 4 A.L.R. 5th 1 (1992); Burris et
al., supra note 3.
65. See Doe v. Bridgeport Police Dep't, 198 F.R.D. 325, 329-330 (D. Conn. 2001); see
also Roe v. City of New York, 232 F. Supp. 2d 240, 246-247 (S.D. N.Y. 2002).
66. See Doe v. Bridgeport Police Dep't, 198 F.R.D. 325; Roe v. City of New York, 232 F.
Supp. 2d 240 (finding for plaintiffs in both cases).
Summer 20031
UNIVERSITY OF SAN FRANCISCO lAW REVIEW
Table III: Syringe Deregulation in the United States
State Year Prior Law(s) Change
OR 1987 Paraphernalia law Syringes explicitly excluded from paraphernalia law
WI 1989 Paraphernalia law Syringes explicitly excluded from paraphernalia law
CT 1992 Prescription law Allowed purchase of 10 or fewer syringes without pre-
scription
Paraphernalia law Allowed possession of 10 or fewer syringes without a pre-
scription (raised to 30 or fewer in 1999 amendment)
ME 1993 Prescription law Allowed the sale of 10 or fewer syringes without a pre-
scription
1997 Paraphernalia law Allowed possession of 10 or fewer syringes
MN 1997 Paraphernalia law Allowed pharmacy sale of up to 10 syringes without a
prescription and the possession of up to 10 unused syr-
inges at a time
NY 2000 Prescription law Allowed the sale of 10 or fewer syringes without a pre-
scription (during two-year experiment)
Paraphernalia law Allowed the possession of legally obtained syringes (dur-
ing two-year experiment)
NH 2000 Prescription law Allowed the purchase of 10 or fewer needles in a phar-
macy without a prescription
Paraphernalia law Syringes excluded from paraphernalia law
RI 2000 Prescription law Repealed
Paraphernalia law Syringes excluded from paraphernalia law
NM 2001 Paraphernalia law Allowed the sale of syringes by licensed pharmacists
HI 2001 Paraphernalia law Exempts sale by medical professionals to IDU for disease
control purposes; exempts possession by IDU
WA 2002 Paraphernalia law Allows pharmacy sale and IDU possession "for the pur-
pose of reducing the transmission of bloodborne dis-
eases"
IL 2003 Prescription law Allowed pharmacy purchase and subsequent possesion of
up to 20 syringes without a prescription
I Paraphernalia law Allowed the possession of legally obtained syringes
purpose behind the 1992 legislation: discouraging needle and syr-
inge exchange program participants from transporting previously-
used injection equipment to the Exchange, and encouraging all
injecting drug users to hastily and likely improperly abandon now-
easily-obtainable injection equipment after one use in order to
avoid arrest.67
We found no data on the number of people prosecuted and im-
prisoned for possession of trace amounts of heroin or other injectable
drugs. One could reasonably assume that the number is small: there is
little glory for prosecutors or police in trying or arresting users, and
one can imagine jurors and judges, particularly in big cities, disfavor-
67. Bridgeport Police Dep't, 198 F.R.D. at 349.
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Table IV. Possession of Trace Amounts of Illegal Drug
Law explicitly or by judicial Law could reasonably be Law explicitly or by judicial
interpretation criminalizes interpreted to criminalize interpretation exempts
possession of trace amount possession of trace amount possession of trace amount
(34) (13) (6)
AL, AX, CO, CT*, DC+, GA, DE, FL, IA, MA, MT, PA, PR, AZ, AR, CA, HI, NV, RI
ID, IL, IN, KS, KY, LA, ME, SD, TN, VT, VI, WV, WY
MD+, MI, MN, MS, MO, NE,
NH, NJ, NM, NY**, NC, ND,
OH, OK OR, SC, TX, UT,
VA, WA, WI
* A federal district court has enjoined enforcement of this law in Bridgeport
+ SEP clients exempt
** A federal district court has declared that this law does not apply to SEP clients
Boldface type indicates crime is a felony
ing efforts to treat small-time use as big time crime. If those assump-
tions are true, raising the minimum amount of drug possessed
necessary to constitute a crime to a specified or "usable" amount
would not have a real impact on the ability of the state to prosecute
and jail people who possessed drugs. Without minimizing the value of
data on these points, however, it is likely that the real value to law
enforcement of these low possession thresholds is in their facilitation
of "street policing."
It has long been recognized that the strategies and legal interpre-
tations of law enforcement officers on the streets can differ from the
law on the books. Police officers have considerable discretion within
the rules to use law to control street situations. Dealing with IDUs,
they can stop and frisk, question, confiscate syringes, warn, or arrest.
Arrest does not necessarily have to be aimed at prosecution and con-
viction upon a major charge, such as drug possession. An officer may
simply use the arrest to get a person off the street for a few hours. A
charge of drug possession based on residue possession may be plea-
bargained to a lesser charge, still occasioning a period of pre-trial im-
prisonment and an addition to the user's criminal record. Many drug
users are already on probation or parole, so that a drug related arrest
or conviction, however minor the charge, may lead to re-incarceration
on the original charge.
C. Syringe Access by Jurisdiction and Mode
Identifying what laws a state has, relevant to syringe access, is only
the first step in the analysis of syringe access legality. Leaving aside
syringe exchange or deregulation laws, the statutes and regulations
discussed above were not written with disease prevention in mind, and
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frequently leave some room for uncertainty as to their applicability to
syringe access initiatives. Even laws that unambiguously prohibit some
forms of syringe access may authorize others: syringe prescription laws
generally prohibit sales without a prescription, but may not prohibit
physicians from prescribing syringes to IDUs. In the absence of an
explicit statute or judicial decision on the precise issue, the determi-
nation of the legality of a mode of syringe access in a particular state is
a matter of professional legal judgment taking into consideration stat-
utory language, legislative intent, case decisions, and social factors.
Such legal analysis is constrained to some extent by norms of interpre-
tation within the legal profession, but these constitute outer bounds
of plausible reasoning, leaving considerable room for reasonable disa-
greement. The conclusions below should thus be understood as pro-
fessionally defensible predictions about how a judge-the legal
official ultimately empowered to say what the law means-would inter-
pret the law in a state. This is reflected by our use of three categories
of legality: "clearly legal" and "clearly illegal"-both indicating that
the plain text of laws or case decisions would be deemed by most law-
yers to authorize or bar the activity-and "reasonable claim to legal-
ity," indicating that an attorney could ethically advise a client that the
law, while unclear, could be interpreted to allow the conduct at issue.
This legal uncertainty is a characteristic and important aspect of syr-
inge access policy and practice.
1. Retail Syringe Sale Without a Prescription
In states without a prescription requirement, the main legal influ-
ences on the retail sale of syringes are drug paraphernalia laws and
statutes or regulations requiring the buyer to demonstrate a legitimate
medical purpose for the purchase. Assessing the legality of over-the-
counter sales in these states is not always clear-cut. As discussed above,
drug paraphernalia laws at most only prohibit the knowing, sale of syr-
inges to an IDU; a seller who does not know of the intended use, and
is not being willfully blind to the clear indications of the user's inten-
tion, does not violate the law. Table V, therefore, addresses the harder
question of whether a knowing sale is legal.
Paraphernalia laws in some states contain exemptions that would
cover at least some knowing retail sales. Moreover, nearly all state par-
aphernalia laws were passed before the HIV epidemic, and were
aimed at the sale of non-medical equipment in stores catering to rec-
reational drug users. In many of these states, it is reasonable to con-
clude that paraphernalia laws were not intended to prohibit sales of a
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medical device like a syringe in retail establishments not catering pri-
marily to drug users, as part of an effort to reduce HIV transmission.
The argument that paraphernalia laws do not apply is particularly
strong in the case of pharmacy sales because pharmacists enjoy special
legal status as licensed sellers of a wide variety of regulated drugs and
devices. This argument is generally not reasonable where legislatures
have subsequently amended paraphernalia laws to allow SEPs. Amend-
ing a paraphernalia law to allow SEPs would not be necessary unless
the legislature believed that syringe sales were generally limited by the
paraphernalia law. The Courts' practice of interpreting statutes that
afford a limited exception to continue to bar activity that has not been
exempted would lead to the same conclusion.
Retail sales may be restricted to pharmacies by explicit provision
of law or regulation or because the generally applicable law prohibit-
ing sales exempts only pharmacists. Other regulations or syringe laws
may also influence sales.
Table V. Retail Sale of at Least Some Number of Syringes to
an IDU, Knowing of the Intended Use
Clearly legal Reasonable claim to legality Clearly illegal
(21) (22) (10)
AK, CT*, HI*, IL*, IN*, LA*, AL*, AR, AZ, CO, FL, ID, IA, CA, DE, DC, GA, KS, MA, NJ,
ME*, MN*, MT*, NH*, NM*, KY, MD*, MI, MO, MS, NE, PA, VT, VI
NY*, OH*, OR, PR, R*, SC*, NV*, NC, ND, OK, SD, TX,
TN*, WV*, WA*, WI UT, VA*, WY
(* denotes sale clearly legal or has a reasonable claim to legality in pharmacy only)
2. Sale with Prescription
Physicians generally have broad discretion to prescribe drugs and
devices they believe will be medically beneficial for patients. 68 A pre-
scription is proper if it is written (1) in good faith, (2) in the course of
normal professional practice, and (3) for a legitimate medical pur-
pose in accordance with treatment principles accepted by a responsi-
ble segment of the medical profession. 69 Pharmacists are authorized
68. See BARRY F. FURROW ET AL., HEALTH LAW (1995); see also CAL. Bus. & PROF. CODE
ANN. § 2051 (West 1998).
69. Lawrence 0. Gostin, The Legal Environment Impeding Access to Sterile Syringes and
Needles: The Conflict Between Law Enforcement and Public Health, 18J. ACQUIRED IMMUNE DEFI-
CIENCY SYNDROMES & HUMAN RETROVIROLOGY S60, S62 (Supp. 1 1998); 21 U.S.C. § 802(21)
(2003); See PA. STAT. ANN. tit. 35, § 780-111(d) (West 2003); United States v. Rosenberg,
515 F.2d 190, 193 (9th Cir. 1975); People v. Schade, 32 Cal. Rptr. 2d 59, 69 (1994); Christo-
pher Vaeth, Annotation: State Law Criminal Liability of Licensed Physician for Prescribing or Dis-
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to dispense medications ordered by a valid prescription and are ordi-
narily expected to do so in the absence of good reason to refuse.
Scott Burris and colleagues 70 examined the legality of physician
prescription of injection equipment to patients as a means of prevent-
ing disease transmission associated with injection drug use. The prac-
tice was clearly legal in 49 of the 53 jurisdictions, while dispensing
prescribed syringes in pharmacies was clearly legal in 28. State law was
considered to provide a reasonable claim to legality in two states with
respect to prescribing and 22 with respect to dispensing. Prescribing
injection equipment was clearly prohibited by law in only two jurisdic-
tions; dispensing was clearly illegal in only three. The legality of nee-
dle distribution through the health care system is thus quite different
than lay distribution through syringe exchanges or pharmacy sale
without prescription. These findings are outlined in Table VI below.
Table VI. Prescription and Sale of Syringes
Physician prescription of sterile injection Pharmacy sale of prescribed
equipment syringes
Reasonable Reasonable
claim to Clearly Clearly claim to Clearly
Clearly legal legality illegal legal legality illegal
(49) (2) (2) (28) (22) (3)
AL, AK, AR, AZ, CA, CO, OH, OK DE, KS AK, CA, CO, AL, AR, AZ, DE,
CT, DC, FL, GA, HI, ID, CT, HI, IL, DC, FL, ID, GA,
IL, IN, IA, KY, LA, ME, IN, LA, ME, IA, KY, MD, KS
MD, MA, MI, MN, MS, MA, MI, MN, MS, MO,
MO, MT, NE, NV, NH, MT, NV, NE, NC,
NJ, NM, NY, NC, ND, NH, NJ, NM, ND, OH,
OR, PA, PR, RI, SC, SD, NY, OR, PA, OK, SD,
TN, TX, UT, VT, VA, VI, PR, RI, SC, TX, UT,
WA, WV, WI, WY TN, VA, WA, VT, VI, WY
WV, WI
3. Syringe Exchange
Syringe exchange continues to grow as a mechanism of sterile
syringe access. Programs reportedly operating in the United States are
summarized in Table VII. In legal terms, SEPs may be placed into four
categories, which are described in Table VIII below. Twelve states and
the District of Columbia have affirmatively authorized syringe ex-
pensing Drug or Similar Controlled Substance, 13 A.L.R. 5th 1, 3 (1994); FRANK M. MCCLELLAN,
MEDICAL MALPRACTICE: LAW, TACTICS AND ETHICS (1994).
70. See Burris et al., Time for Action, supra note 36, at 220 (We have updated their
results to take into consideration subsequent changes in state law.); Burris et al., Harm
Reduction, supra note 36 at 8.
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change programs. Seven states-Connecticut, Hawaii, Maine, Mary-
land, New Mexico, Rhode Island and Vermont-and the District have
done so by passing laws establishing programs. (In Maryland, SEPs are
authorized in Baltimore only. In New Hampshire, though authorized
by law, no SEP has actually been approved to operate by the health
department). Two states-California and Massachusetts-have dele-
gated the decision to allow SEPs to local governments. In New York,
syringe exchange programs are authorized by the Commissioner of
Health exercising power granted in the paraphernalia law to waive its
application. 71 In Washington, local health officials secured a declara-
tory judgment from the state Supreme Court holding that the para-
phernalia law did not prohibit them from authorizing syringe
exchange programs, a ruling that was later codified by the legislature.
Syringe exchanges in three states are presently operating by au-
thority of local government, without explicit authorization from state
authorities. In Philadelphia, Allegheny County (PA), and Cleveland,
local officials determined that their public health authority extended
to authorizing syringe exchange, despite the existence of state laws
otherwise limiting syringe access to IDUs. In Chicago, local law en-
forcement and health officials have interpreted a "research" exemp-
tion from the paraphernalia law to encompass SEPs. While these
interpretations are legally debatable, they are also legally reasonable
and have proven a politically expedient way to operate SEPs in states
unlikely to change their law. In five states, the law does not regulate
the free distribution of syringes, and therefore does not prohibit syr-
inge exchange.
Syringe exchange programs operate in at least nineteen states
without a specific claim to legality. The laws in these states may or may
not clearly forbid SEPs, but these SEPs nevertheless are able to oper-
ate through more or less tacit arrangements with law enforcement au-
thorities. In some of these states, such as Massachusetts, illegal
exchanges operate along with legally authorized ones, usually in areas
where legal exchange does not operate or is regarded as insufficient
by the non-sanctioned exchange providers. Where there is no explicit
authorization for SEPs, the legality of syringe exchange or other
modes of free distribution depends upon the specific language and
case law under any applicable syringe prescription, drug parapherna-
lia and pharmacy practice laws. Based on a review of reported cases,
New Jersey is the only state without any legal needle access in which
71. N.Y. PuB. HEALTH LAw § 3381 (Consol. 2003).
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Table VII: Syringe Exchange Programs in the United States
(Adapted from Singh et al. 2001)
State SEPs Comments
Alaska I
Arizona I SEPs receive public funding
California 21 SEPs receive public funding & Los Angeles and San
Francisco have multiple SEI's
Colorado 2 SEPs receive public funding
Connecticut 6 SEPs receive public funding
DC I
Georgia I
Hawaii 1 SEPs receive public funding
Illinois 2 SEPs receive public funding
Indiana 2 Indianapolis has multiple SEPs
Kansas I
Louisiana I
Maryland 1 SEPs receive public funding
Massachusetts 5 SEPs receive public funding
Michigan 3 Detroit has multiple SEPs
Minnesota 2 Minneapolis has multiple SEPs
Montana 2
New Hampshire 1
New lersey 1 Subsequently closed down by police action
New Mexico 9 SEPs receive public funding
New York 14 SEPs receive public funding & New York City has multiple
SEPs
North Carolina 1
Ohio 2
Oklahoma I
Oregon 3 SEPs receive public funding & Portland has multiple SEPs
Pennsylvania 3 SEPs receive public funding
Puerto Rico 2 SEPs receive public funding
Rhode Island 1 SEPs receive public funding
Tennessee I
Texas 2
Utah 1
Washington 12 SEPs receive public funding & Seattle and Tacoma have
multiple SEPs
Wisconsin 3 SEPs receive public funding
Total Number Total = 110
of States = 33
Five other cities asked that their program information be kept confidential
lay exchangers have actually been convicted of a syringe law violation.
The fact that an exchange operates without a clear legal basis does not
necessarily mean that such a basis could not be identified. In Colo-
rado, for example, local governments have substantial authority to
deal with local health threats, and so a city would have a reasonable
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Table VIII: Legal Status of Syringe Exchange Programs in the
U.S. (Some data from Singh et al. 2001)
SEP authorized by local Free distribution of SEP(s) operating
SEP authorized by government based on its syringes not without specific claim
state law interpretation of state law restricted by state law to legality - 1998
(13) (3) (5) (19)
CA, CT, DC, HI, IL, OH, PA AK, LA, OR, RI, WI AZ, CO, GA, IN, KS,
ME, MA, MD, MA, MI, MN, MT, NJ,
NH, NM, NY, RI*, NY, NC, OK, PA, PR,
VT, WA TN, TX, UT, WA
* State law no longer restricts free distribution
basis for authorizing an SEP under its own authority. Research has not
been performed on the legal authority of most cities to authorize syr-
inge exchange.
Syringe exchanges explicitly authorized by statute are subject to a
variety of rules concerning the manner in which they may distribute
syringes and the services they must offer. Strict one-for-one exchange
policies are often required by policy makers to placate concerns that
SEPs could lead to an increase in improperly discarded syringes or
encourage initiation of injection among youth.72 These rules, which
like the "ten and under" cap reflect political rather than public health
imperatives, may have in some instances a significant impact on the
effectiveness of official SEPs, and may explain why illegal or unofficial
SEPs may continue to operate in states that have authorized legal pro-
grams. These limits are summarized in Table IX. SEP operating poli-
cies not explicitly required by applicable law may also influence
syringe access. For example, some SEPs follow a "high access" model
that focuses on direct contact with each IDU, rather than a "high vol-
ume" model that aims for maximum dissemination of syringes. Some
high-access SEPs have actively discouraged secondary exchange-giv-
ing large numbers of syringes to exchange clients with the expectation
that they will be given or sold to others-despite some evidence that
secondary exchange could enhance the effectiveness of syringe
exchange. 73
72. See LURIE E'r AL., supra note 10, at 17-19.
73. See Carl A. Latkin, & Valerie L. Forman, Patterns of Needle Acquisition and Soci-
obehavioral Correlates of Needle Exchange Program Attendance in Baltimore, Maryland, U.S.A, 27J.
ACQUIRED IMMUNE DEFICIENCY SYNDROMES 398, 401-402 (2001); Thomas W. Valente et al.,
Satellite Exchange in the Baltimore Needle Exchange Program, 113 PUB. HEALTH REP. 90 (Supp. 1
1998).
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D. Syringe Disposal
Syringe disposal has emerged as another important facet of syr-
inge access policy. The prospect of providing syringes to IDUs some-
times triggers concerns that needles contaminated with HIV will be
carelessly discarded in schoolyards or other inappropriate places. For
example, in Windham, Connecticut, the SEP was closed in significant
part because of allegations that users were discarding needles in the
surrounding community.74 Generally, however, an effective mecha-
nism for safe syringe disposal is inherent in the SEP intervention. Dis-
posal is an explicit part of SEP regulation in only four states, but SEPs
typically provide one new syringe for every used syringe turned in, or
in some other way tie the number of needles given out to the number
returned. Thus, syringe exchange programs do not increase the time
that potentially contaminated syringes circulate in the community
and, indeed, reduce the number of inappropriately discarded ones.75
Empirical studies of discarded syringes in the vicinity of syringe ex-
change programs have documented the absence of increases in un-
safely discarded syringes.76
The disposal issue has loomed even larger in the development of
deregulation policies, because deregulation laws may expand syringe
availability without necessarily providing new means of safe disposal.
Recent deregulation laws, including Minnesota's and New York's,
have dealt with the disposal question by mandating information on
disposal for buyers and encouraging voluntary disposal programs or
referral efforts by sellers. A pre- and post-deregulation study by the
Minnesota Department of Health found that the proportion of IDUs
using officially approved means of syringe disposal did not change af-
ter pharmacy sales were legalized (remaining at about 20%).
[A]lthough most disposal methods used by IDUs were classified as
being unsafe, most of these methods did not pose a serious threat
to the general public .... Over 94% of these unsafe disposal meth-
ods included some variation of the following: placing a capped syr-
74. Robert S. Broadhead, The Impact of a Needle Exchange's Closure, 114 PUB. HEALTHl
REP. 439, 439 (1999).
75. Kathy J. Oliver et al., Impact of a Needle Exchange ProgTam on Potentially Infectious
Syringes in Public Places, 5 J. ACQUIRED IMMUNE DEFICIENCY SYNDROMES 534 (1992); Meg C.
Doherty et al., Discarded Needles Do Not Increase Soon After the Opening of a Needle Exchange
Program, 145 Am.J. EPIDEMIOLOGY 730, 730 (1997); see also Kaveh Khoshnood et al., Syringe
Source, Use, and Discard among Injection-Drug Users in New Haven, Connecticut, 15 AIDS PUB.
POL'YJ. 88, 92, 94 (2000) (IDUs using SEP significantly less likely to report throwing away
syringes than pharmacy purchasers).
76. Doherty et al., supra note 75, at 731; Oliver et al., supra note 75, at 534.
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inge in a soda can or other container that is then crushed and
thrown in the trash.77,,
But if the early evidence is that pharmacy availability does not
make the disposal problem worse-e.g. does not lead to disposal in
parks-it also points to the overall lack of safe disposal options for
needles used outside the health care system.
In the United States, over 3 billion syringes are used each year in
community settings (i.e., outside health care facilities), and are depos-
ited into the general waste stream. 78 Discarded needles are a source of
injury and anxiety to workers in' trash disposal, recycling, and related
occupations. Most of these syringes come from people administering
medications for conditions such as diabetes, but many are attributable
to IDUs. 79 The American Medical Association's Council on Scientific
Affairs, summarizing the results of a national conference on disposal,
reported that "there are no defined regulations or laws that guide the
disposal of sharps in the community."81 While states may have their
own system for handling the community disposal of used sharps, many
are not successful and guidelines that do exist are conflicting and
often inappropriate. "This has led to confusion among stakeholders
regarding the proper disposal of used sharps in the community."81
Only a few communities have locally-administered programs for syr-
inge disposal.8 2
The problem is not merely a lack of regulation, but also the ef-
fects of substantial regulation that pertains to but does not adequately
address community syringe disposal. Dealing with the disposal of
needles puts any policy reformer at the intersection of several com-
plex, overlapping regulatory systems. Discarded syringes may be sub-
ject to regulation under general state solid waste management statutes
77. Niki U. Cotten-Oldenburg et al., Impact of Pharmacy-Based Syringe Access on Injection
Practices Among Injecting Drug Users in Minnesota, 1998 to 1999, 27J. ACQUIRED IMMUNE DEFI-
CIENCY SYNDROMES 183, 190 (2001).
78. Disposing of Hypodermics: Stuck with a Needle Problem, AM. MED. NEWS, July 30, 2001,
at http://www.ama-assn.org/sci-pubs/amnews/amn-O1/edsaO730.htm.
79. Grace E. Macalino et al., Community-Based Programs for Safe Disposal of Used Needles
and Syringes, 18 J. ACQUIRED IMMUNE DEFICIENCY SYNDROMES & HUMAN RETROVIROLOGY
Sill, S113, S117 (Supp. 1 1998).
80. COUNCIL ON SCIENTIFIC AFFAIRS, AM. MED. ASS'N, SAFE DISPOSAL OF SYRINGES, NEED-
LES, AND OTHER SHARPS IN THE COMMUNITY, Report A-01 (2001), available at http://www.
ama-assn.org/aina/pub/article/2036-4965.html.
81. Id.
82. See Macalino et al., supra note 79, at S118; see also E. Riley et al., Operation Red Box:
A Pilot Project of Needle and Syringe Drop Boxes for Injection Drug Users in East Baltimore, 18
J.AcQUIRED IMMUNE DEFICIENCY SYNDROMES & HUMAN RETROVIROLOGY S120 (Supp. 1 1998).
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or under specific statutes dealing with medical waste. 83 These, how-
ever, often exempt syringes generated in individual, community use.
The Occupational Safety and Health Administration's Bloodborne
Pathogen standard applies to workers who may reasonably anticipate
coming into contact with used syringes..84 The standard requires em-
ployers to write an Exposure Control Plan setting out tangible steps
for reducing worker risk. Some states have created voluntary guide-
lines for community disposal, advising syringe users, for example, to
dispose of syringes in coffee cans or plastic milk containers. Use of the
mail as a means of returning community syringes for proper disposal
is governed by U.S. Postal Service Regulations and some states' solid
waste law.8 -5 Finally, the array of laws governing syringe and drug pos-
session may also influence disposal, to the extent that fear of arrest
may make IDUs unwilling to follow through on safe disposal of their
used, blood-contaminated syringes.8 6
Many of these regulations may raise the cost or limit the options
for any agency, business, or community group willing to undertake
responsibility for disposal. At the same time, the overlapping of juris-
diction leaves unclear who is ultimately responsible for syringes dis-
posed in the community. Of course, a system of syringe disposal is not
free, adding the difficult question of who should bear the cost to the
policy dilemma. Although the data are only now being systematically
collected, there are reports of agencies at the state and local level de-
veloping community syringe disposal models, and waste management
providers have experimented with mail-back disposal systems in at
least one state. Developing a coordinated approach and appropriate
funding mechanism for collecting community-generated syringes is an
important policy priority that may require legislative action at the state
or federal level.
To the extent that safe systems of community sharps disposal are
implemented, the syringe access laws set out earlier may act as barriers
to participation by IDUs. Community disposal programs usually re-
quire the participant to dispose of syringes in specially designed or
labeled containers placed in regular trash, or to take the needles to a
83. ALA. CODE § 22-27-1-22-27-7 (2003); Alabama Department of Environmental Man-
agement Admin. ALA. ADMIN. CODE r. 335-13-7.01-335-13-7.10 (2003).
84. 29 C.F.R. § 1910.1030 (2003).
85. See 39 C.F.R. § 111.1 (2003).
86. Kristen W. Springer et al., Syringe Disposal Options for Injection Drug Users: A Commu-
nity-Based Perspective, 34 SUBSTANCE USE & MISUSE 1917, 1929 (1999); Cotten-Oldenburg et
al., supra note 77, at 189.
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designated community disposal site. 87 In either case, an IDU would
have to accumulate used needles, many of which would contain drug
residue, and dispose of them in a way or in a place that makes conceal-
ment difficult. To the extent that possession, use of syringes for drug
use, or possession of trace amounts of an illegal drug are crimes, par-
ticipating in safe disposal creates a legal risk for IDUs. As one IDU put
it, "They'd [the police] catch you with a dirty syringe and you'd go to
jail for possession, so people ain't hardly gonna keep 'em laying
around, keep 'em in a container or whatever."88
Burris and colleagues reviewed syringe access and drug posses-
sion laws to determine whether they could be interpreted to criminal-
ize the possession of a used syringe by an IDU. 9 Drug possession laws
could be applied to trace amounts in forty-seven jurisdictions. Taking
into account the two jurisdictions without a paraphernalia law, the fif-
teen states that have authorized at least some possession of syringes
(through deregulation, syringe exchange legislation or otherwise),
and six other jurisdictions whose paraphernalia laws regulate only sale
(Massachusetts, Michigan, Vermont, Virginia, West Virginia, Wyo-
ming), the study found thirty jurisdictions whose paraphernalia laws
make it a crime for an IDU to possess a used syringe. In three of these
(Arizona, Delaware, North Dakota), the crime is a felony. Prescription
laws in six jurisdictions (California, Delaware, Nevada, NewJersey, Vir-
ginia, Virgin Islands) also prohibit possession of syringes without a
prescription. Together, these provisions operate to create at least po-
tential criminal liability for IDUs participating in safe disposal activi-
ties in all but two states. For complete results see Table X.
From a policy perspective, the most significant finding of the
study is that these barriers exist even in most of the states that have
deliberately adopted policies affording IDUs legal access to syringes
(and indeed even in states that have mandated that syringe purchasers
be given information about safe disposal). In these states, the specific
barrier is usually a drug possession provision, which may not have
been addressed because of a lack of awareness of the 'way that drug
possession laws are tied to disposal, or because of political reluctance
to "weaken" drug possession laws by excluding the possession of resi-
due. In some states, the failure to remove barriers to disposal may also
reflect the legal complexity of syringe access and drug possession law;
in New Mexico, for example, legislation to ease syringe access re-
87. See Macalino et al., supra note 79, at S112.
88. Springer et al., supra note 86, at 1923.
89. See Burris et al., supra note 3.
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Table X. Disposal Disincentives
BOTH a syringe and drug EITHER a syringe or drug NO syringe or drug law
possession provision that could possession provision that could barriers to IDU
deter IDU participation in safe deter IDU participation in safe participation in safe
disposal disposal disposal
(29) (22) (2)
AL, CO, DE, DC*, FL, GA, ID, AK, AZ, AR, CA*, CT*, IL*, HI*, RI*
IN, IA, KS, KY, LA, MA*, MD*, ME*, MI*, MN*, NV*, NH*,
MS, MO, MT, NE, NJ, NC, ND,, NM*, NY*, OR*, PR, SC, VT*,
OH, O, PA, SD, TN, TX, UT, WA*, WV, W*, WY
VA, VI
* State has authorized SEP, fully or partly deregulated syringes to' prevent blood borne disease,
or otherwise acted to enhance syringe access for IDUs
moved legal barriers to the sale of syringes to IDUs, but apparently
inadvertently did not legalize, their possession once purchased.9° Nev-
ertheless, some policy makers have .recognized and addressed the
problem in part; in the District of Columbia and Maryland, syringe
exchange legislation explicitly immunized SEP clients (though not
other IDUs) from prosecution for the possession of residues.
IV. Research Regarding the Effects of Syringe Access
Policies
Both sides in the debate over enhancing syringe access frequently
rely on health research data to support their positions. A large body of
literature exists on injection drug use, law and health, although sev-
eral questions that have been crucial in policy debate have not been
clearly answered. In this section, we will highlight research addressing
the most important factual findings for policy. These issues are
whether restrictive syringe access laws do indeed influence the ability
of IDUs to purchase syringes, whether removing some or all legal bar-
riers to syringe access is effective in enhancing syringe access and re-
ducing needle sharing, and whether changes in syringe law have
adverse health or societal consequences, such as increasing drug use
or crime. Although the research generally is of high quality-it has, as
we observed at the outset, convinced us of the value of syringe access
to public health-there are methodological limitations associated
with studying syringe access. There is also a paucity of research in spe-
cific areas such as the effects of deregulation of syringe laws or phar-
macy access. Because sound policy depends upon sound data, and
because policy debates are often framed in terms of empirical evi-
90. See Controlled Substances Act, N.M. STAT. ANN. § 30-31-25.1 (Michie 2002).
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dence, we conclude by discussing the limits of data and the implica-
tions of those limits for policy development.
A. The Effects of Syringe Access Laws on the Ability of IDUs to
Purchase Syringes
Syringe access laws were intended to prevent IDUs from ob-
taining syringes. Research shows that syringe laws do not prevent IDUs
from obtaining the syringes they need for injecting drugs, but they
generally do make it more difficult for IDUs to obtain and keep sterile
syringes in their possession.
The effect of these laws varies with their specific type and strin-
gency. Prescription laws appear to have the most consistently negative
impact on syringe access. They are unambiguous, leaving the pharma-
cist virtually no discretion. They generally entail the maintenance of
records that can be reviewed by pharmacy or drug-control authorities,
heightening their deterrent effect. Possession of a syringe without a
prescription is also a crime under these laws, which have been found
to be regularly enforced in states where research has been done.91 An
immediate effect is seen in the price of "street" syringes: a survey of
SEP personnel in eighteen states found that street prices rose steadily
and substantially according to whether there was no syringe posses-
sion law, an unenforced law, or an enforced law.92 Friedman and col-
leagues found that prescription laws in the United States were
associated with a higher incidence and prevalence of HIV infection. 93
Prescription laws indirectly prohibit SEP operation and have
been used to prosecute syringe exchange personnel. 94 In 1996, nearly
a quarter of SEPs operating in the United States were illegal under-
ground programs. 95 The same year, over half of all SEPs in the United
91. Patricia Case, Arrests and Incarceration of Injection Drug Users for Syringe Possession in
Massachusetts: Implications for HIVPrevention, 18J. ACQUIRED IMMUNE DEFICIENCY SYNDROMES
S71, S72 (Supp. 1 1998); see also Josiah D. Rich et al., High Street Prices of Syringes Correlate
with Strict Syringe Possession Laws, 26 Am. J. DRUG & ALCOHOL ABUSE 481, 482-83 (2000)
[hereinafter Rich et al., High Street Prices]; Josiah D. Rich et al., Strict Syringe Laws in Rhode
Island Are Associated with High Rates of Reusing Syringes and HIV Risks among Injection Drug
Users (Letter), 18J. ACQUIRED IMMUNE DEFICIENCY SYNDROMES S140, S140 (1998) [hereinaf-
ter Rich et al., Letter].
92. Rich et al., High Street Prices, supra note 91, at 484-85 (These results were signifi-
cant at the .01 level.).
93. Samuel R. Friedman et al., Laws Prohibiting Over-the-Counter Syringe Sales to Injection
Drug Users: Relations to Population Density, HIV Prevalence, and HIV Incidence, 91 Am. J. PUB.
HEALTi-I 791, 791 (2001); see also Rich et al., Letter, supra note 91, at 791.
94. See Burris et al., supra note 13, at 1163.
95. See D. Paone et al., supra note 23, at 43.
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States reported police harassment of clients, and one quarter re-
ported police harassment of SEP staff or volunteers. 96 At least three
dozen SEP volunteers have been arrested in 21 cities and 8 states since
1986.97 Although few studies have assessed the impact of police pres-
sure on SEP activities, some studies have reported that such arrests
have reduced SEP attendance, limited their expansion, and may have
increased the length of time contaminated needles circulated on the
streets.98 Heimer and colleagues concluded that "[a] mong the many
structural impediments SEPs face, none may be more important than
their legal status."99  . . !'
Because syringes are normally sold in pharmacies, pharmacy reg-
ulations, which are directed primarily at pharmacists, are probably al-
most as significant a barrier to syringe access as prescription
requirements. 10 0° Being required to show an ID, or to prove medical
need (e.g., diabetes), may deter many IDUs from even trying to
purchase syringes. Research indicates that pharmacists are generally
aware of, and are intent on complying with, pharmacy regulations. 0 1
Unlike prescription laws, however, these pharmacy regulations allow
pharmacists a fair amount of discretion. For example, a South Caro-
lina pharmacist may decide that preventing blood borne disease is a
"legitimate medical purpose" justifying sale, or may accept without
further evidence the buyer's claim to be a diabetic. In recent years,
pharmacy boards in Washington, Maine, Maryland, and Nevada have
taken formal or informal action to encourage pharmacists to exercise
their discretion to sell syringes to IDUs.
96. Ricky N. Bluthenthal et al., Use of an Illegal Syringe Exchange and Injection-Related
Risk Behaviors Among Street-Recruited Injection Drug Users in Oakland, California, 1992 to 1995,
18J. ACQUIRED IMMUNE DEFICIENCY SYNDROMES & HUMAN RETROVIROLOcY 505, 506 (1998).
97. Id.; see also Ricky N. Bluthenthal Syringe Exchange as a Social Movement: A Case Study
of Harm Reduction in Oakland, California, 33 SUBSTANCE USE & MISUSE 1147, 1153 (1998);
LURIE ET AL., supra note 10.
98. See Ricky N. Bluthenthal, Impact of Law Enforcement on Syringe Exchange Programs: A
Look at Oakland and San Francisco, 18 MED. ANTHROPOLOGY 61, 71 (1997); see generally Rob-
ert Heimer et al., Structural Impediments to Operational Syringe-Exchange Programs, 11 AIDS &
PUB. POL'YJ. 169, 172 (1996).
99. Heimer et al., supra note 98, at 171.
100. Jennifer A. Taussig et al., Syringe Laws and Pharmacy Regulations Are Structural Con-
straints on HIV Prevention in the US, 14 AIDS S47 (Supp. 1 2000).
101. Alice A. Gleghorn et al., Pharmacits'Attitudes About Pharmacy Sale of Needles/Syringes
and Needle Exchange Programs in a City Without Needle/Syringe Prescription Laws, 18 J. ACQUIRED
IMMUNE DEFICIENCY SYNDROMES S89 (1998); P. Case et al., Access to Sterile Syringes in Maine:
Pharmacy Practice Afler the 1993 Repeal of the Syringe Prescription Law, 18 J. ACQUIRED IMMUNE
DEFICIENCY SYNDROMES S94 (Supp. 1 1998).
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Paraphernalia laws appear to be enforced against IDUs who pos-
sess syringes. In a 1995 Connecticut study, seven of 147 IDUs reported
recent paraphernalia arrests, as did plaintiffs and witnesses in a recent
Connecticut law suit. 1(2 Ethnographic research among IDUs has re-
peatedly found that fear of arrest is a factor in whether or not IDUs
carry their own syringes with them when they are purchasing and us-
ing drugs." 3 Arrests, or fear of arrest, can lead to circumstances where
needle sharing is inevitable. 10 4
The effect of paraphernalia laws on IDU's ability to purchase syr-
inges is uncertain, in large part because the applicability of parapher-
nalia laws to pharmacy sales is unclear.10 5 Although the language of
the typical paraphernalia law would embrace the knowing sale of a
syringe to an IDU for drug consumption, paraphernalia laws do not
require pharmacists to question a syringe purchaser about the in-
tended use. A search of reported cases by Burris and colleagues found
no instance in which a pharmacist had been prosecuted under a para-
phernalia law or pharmacy regulation for improperly selling a syr-
inge. 10 6 Research among pharmacists indicates that most are either
not specifically aware of paraphernalia laws or that these laws do not
figure heavily into their decisions to sell syringes."1 7 Paraphernalia
102. Jean-Paul C. Grund et al., In Eastern Connecticut, IDUs Purchase Syringes from Pharma-
cies but Don't Carry Syringes (Letter), 10J. ACQUIRED IMMUNE DEFICIENCY SYNDROMES 104, 105
(1995); Doe v. Bridgeport Police Dep't, 198 F.R.D. 325, 330 (D. Conn. 2001). Accord Rich
et al., High Street Prices, supra note 91, at 484.
103. Stephen Koester, Copping, Running, and Paraphernalia Laws: Contextual and Needle
Risk Behavior among Injection Drug Users in Denver, 53 HUMAN ORG. 287, 291 (1994); see Phi-
lippe Bourgois, The Moral Economies of Homeless Heroin Addicts: Confronting Ethnography, HIV
Risk, and Everyday Violence in San Francisco Shooting Encampments, 33 SUBSTANCE USE & MIS-
USE 2323, 2336 (1998); Michael C. Clats et al., The Impact of DrugParapheralia Laws on HIV
Risk Among Persons Who Inject Illegal Drugs: Implications for Public Policy, in How TO LEGALIZE
DRUGS 80, 91-92 (J.M. Fish ed., 1998); Jean-Paul Grund et al., Drug Use Contexts and H1V-
Consequences: The Effect of Drug Policy on Patterns of Everyday Drug Use in Rotterdam and the
Bronx, 87 BRriSii J. ADDICTION 381, 386 (1992); see David Metzger et al., Risk Factors for
Needle SharingAmong Methadone-Treated Patients, 148 AM. J. PSYCHIATRY 636, 639 (1991); Lisa
Maher, & David Dixon, Policing and Public Health: Law Enforcement and Harm Minimization in
a Street-Level Drug Market, 39 BRIT. J. CRIMINOLOGY 488, 499 (1999).
104. Koester, supra note 103, at 291.
105. See Burris et al., Time for Action, supra note 36, at 221-222.
106. Id. at 223.
107. See Stephen K. Koester et al., Role of Pharmacists in Increasing Sterile Syringe Accessibil-
ity: A Formative Study, Paper presented at the National HIV Prevention Conference (At-
lanta, GA 1999); see also Claire E. Sterk et al., Pharmacists'Syringe Sale Practices with Injection
Drug Users in Atlanta, Georgia, Paper presented at the National HIV Prevention Conference
(Atlanta, GA 1999); see Merrill Singer et al., Pharmacy Access to Syringes Among Injecting Drug
Users: Follow-up Findings from Hartford, Connecticut, 113 PUB. HEALTH REP. 81, 82 (Supp. 1
1998); Case et al., supra note 101, at S96-S97; Gleghorn et al., supra note 101, at S91;J.
[Vol. 37
SYRINGE ACCESS
laws have been a barrier to SEPs, though in several states they have
been interpreted by courts or local officials not to bar exchange
programs. 108
Studies examining deregulation also suggest that the legal rules
governing syringe access and possession influence drug users' behav-
ior, although changes in law may not immediately have their intended
effects. Despite a 1992 change in Connecticut laws that allowed the
purchase of up to ten syringes without a prescription, only 30% of
IDUs surveyed after the new law took effect reported that they regu-
larly carried their own syringes. The majority (65%) cited fear of ar-
rest as the main reason for not carrying syringes in public. 0 9
Nevertheless, over a three year period in Connecticut (1992-1995),
the proportion of IDUs who shared syringes decreased from 71% to
29%.110 A Minnesota study comparing IDUs' behaviors before and af-
ter the state legislation repealed syringe prescription laws found that
IDUs were more likely to purchase syringes and were less likely to
share needles, but there were no changes in the proportions who car-
ried or re-used syringes, or safely disposed of syringes."' In their re-
port of needle use practices in Seattle, Washington, where needle
purchase is legal, Calsyn and colleagues' 2 observed lower rates of
needle sharing compared to regions where needle purchase and pos-
session was illegal. Furthermore, a recent analysis suggests that such
restrictions on syringe access have in fact influenced HIV acquisition.
In an analysis of 96 metropolitan areas in the United States, Friedman
and colleagues' 1 3 found that metropolitan areas with anti-over-the-
counter syringe laws had a significantly higher mean HIV prevalence
(13.8% versus 6.7%) than other metropolitan areas. These authors
concluded that laws restricting syringe access are associated with HIV
transmission and should be repealed. However, the impact of a repeal
in syringe prescription laws may be limited in settings where parapher-
nalia and possession laws persist.
Taussig et al., Individual and Structural Influences Shaping Pharmacists'Decisions to Sell Syringes
to Injection Drug Users in Atlanta, Georgia, 42 J. Am. PHARM. ASS'N (6 Supe. 2) S40 (2002).
108. Burris et al., supra note 13, at 1164.
109. Grund et al., supra note 102, at 105.
110. Theresa Diaz et al., Injection and Syringe Sharing among HIV-Infected Injection Drug
Users: Implications for Prevention of HIV Transmission, 18J. ACQUIRED IMMUNE DEFICIENCY SYN-
DROMES & HUMAN RETROVIROLOGY S76, S77 (1998).
111. Cotten-Oldenburg et al., supra note 77, at 185-86.
112. Donald A. Calsyn et al., Needle-Use Practices among Intravenous Drug Users in an Area
Where Needle Purchase Is Legal, 5 AIDS 187, 191-192 (1991).
113. Friedman et al., supra note 93, at 792.
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In the majority of states, which have only a paraphernalia law and
perhaps some pharmacy regulations, the sale of syringes to IDUs is
largely at the discretion of the individual pharmacist. Pharmacists vary
considerably in their willingness to sell syringes, as well as in the prices
they charge." 4 Race, gender, and over-all appearance were related to
the ability to purchase syringes in some but not all experimental syr-
inge buying studies. 15 Store or chain policies were identified as im-
portant factors in some studies'."I6 Pharmacists also report restrictive
sales practices not required by law. These include requiring the buyer
to provide photo identification, a prescription, a diabetes ID, or the
name and address of their doctor." 7 Applicable law, particularly phar-
macy law, appears to play into the pharmacists' decisions to sell syr-
inges to IDUs, but other factors, such as store or chain policies,
attitudes towards IDUs and harm reduction, or fear that selling syr-
inges to IDUs will attract an unsavory clientele are also important.' 8
Studies of pharmacist syringe sale practices suggest that attitudes to-
wards the activity are more important to pharmacist behavior than
law, at least in states not requiring a prescription.
While laws clearly have a serious impact on access to equipment
and its use, law is not the only factor. Individual-level factors, gender
dynamics, social norms, and the need to relieve symptoms of with-
drawal are also important determinants of needle sharing behav-
iors. 119 Even in settings where there are no legal limits to sterile
syringe acquisition by IDUs (e.g., Holland),' 120 needle sharing has not
been entirely eliminated. However, it is clear that this is not a neces-
114. See Koester, supra note 103, at 289; Broadhead, supra note 74, at 446; Wilson M.
Compton, III et al., Legal Needle Buying in St. Louis, 82 AM. J. PuB. HEALTH 595, 596 (1992);
Case et al., supra note 101, at S96; C.R. Harbke et al., Telephone Survey of Alaskan Pharmacists'
Nonprescription Needle-Selling Practices, 77 J. URB. HEALTH 113 (2000). Beth N. Trubatch et
al., Nonprescription Pharmacy Sales of Needles and Syringes, 90 AM. J. PUB. HEALTH 1639, 1639
(2000); F.S. Bridges et al., Sale of Nonprescription Syringes to Men and Women-Florida, 1994-
1995, 1 FLA. J. PHARMACY 12 (1998).
115. Trubatch et al., supra note 114, at 1639; Koester, supra note 103; Bridges et al.,
supra note 114.
116. Harbke et al., supra note 114.
117. Case et al., supra note 101, at S97; see Gleghorn et al., supra note 101, at 891;
Taussig et al., supra note 107, at $90-$91.
118. Ted Myers et al., Community Pharmacist Perspectives on HI VIAIDS and Interventions for
Injection Drug Users in Canada, 10 AIDS CARE 689, 696 (1998); Harbke et al., supra note 114.
119. Carl Latkin et al., People and Places: Behavioral Settings and Personal Network Character-
istics as Correlates of Needle Sharing, 13J. ACQUIRED IMMUNE DEFICIENCY SYNDROMES & HUMAN
RETROVIROLOGY 273, 277 (1996); Steffanie A. Strathdee et al., Social Determinants Predict
Needle-Sharing Behaviour Among lnjection Drug Users in Vancouver, Canada, 92 ADDICTION 1339,
1345 (1997).
120. J.A.R. van den Hoek et al., supra note 8, at 1357.
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sary requirement since cities such as New York and Amsterdam have
essentially reversed their HIV epidemic among IDUs without eliminat-
ing needle sharing altogether. 21 Nevertheless, the evidence supports
the view that changing policy can have the desired effect of decreasing
needle sharing levels in a community, and in turn, decreasing the like-
lihood of an HIV epidemic. An important goal is to determine the
optimal levels of sterile syringe access that are required to prevent or
reverse an epidemic of HIV or other blood borne infections.
Summary: Available data indicate that syringe access laws make it
harder for IDUs to obtain new syringes and create disincentives to
carry them. While these laws do interfere with access to and use of
new, sterile syringes, they do not prevent IDUs from getting some sort
of syringe and injecting drugs. In most places in the United States,
pharmacists make the decision about whether or not an IDU will be
able to purchase a sterile syringe. Law has some influence on this deci-
sion, but a number of surveys of pharmacists' attitudes and practices
indicate that other considerations, including views on health and drug
use, play a stronger role. Thus, although syringe access law is clearly
an important factor in determining whether IDUs will have and use
sterile syringes, it is only one of many.
B. Evidence of the Health Effects of Syringe Access Initiatives
Data on the effectiveness of syringe access has been reviewed ex-
tensively elsewhere. 122 In this section, we briefly recount the main
findings.
Almost all of the international literature investigating syringe ac-
cess and health effects has focused on the relationship between SEPs
and blood borne infections. SEPs have been associated with a number
of positive health outcomes. As early as 1986, Buning and colleagues
from Amsterdam reported declines in needle sharing and injection
frequency associated with SEP participation.1 23 "Other studies subse-
121. See Eric J.C. van Ameiden & Roel A. Coutinho, Maximum Impact of HIVPrevention
Measures Targeted at Injecting Drug Users, 12 AIDS 625, 631-632 (1998); D. Des Jarlais et al.,
Behavioral Risk Reduction in a Declining HIV Epidemic: Injection Drug Users in New York City,
1990-1997, 90 AM.J. PUB. HEALTH 1112, 1116 (2000).
122. Normand et al., supra note 10; LURIE ET AL., supra note 10; David R. Gibson et al.,
Effectiveness of Syringe Exchange Programs in Reducing HIV Risk Behavior and H1V Seroconversion
Among Injecting Drug Users, 15 AIDS 1329 (2001); Strathdee & Vlahov, supra note 9; F.I.
Bastos & S.A. Strathdee, Evaluating Effectiveness of Syringe Exchange Programmes: Current Issues
and Future Prospects, 51 Soc. ScI. & MED. 1771 (2000).
123. See E.C. Buning et al., Preventing AIDS in Drug Addicts in Amsterdam, I LANCET 1435,
1435 (1986).
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quently reported reductions in incidence of HIV, HBV [hepatitis B
virus] and HCV [hepatitis C virus] infections, decreased needle shar-
ing among HIV-negative and HIV-positive persons, decreases in syr-
inge re-use and increased rates of entry into drug treatment
programs." 124
In the United Kingdom and Australia, where SEPs were intro-
duced early and vigorously within the context of a comprehensive pre-
vention program including expanded methadone maintenance
programs, HIV epidemics among IDUs have been essentially
averted. 125 Despite variations between programs, a recent interna-
tional comparison showed that in 29 cities with established SEPs, HIV
prevalence decreased on average by 5.8% per year, but increased on
average by 5.9% per year in 52 cities without SEPs. 126 In New York
City, SEPs have been associated with a dramatic decline in the inci-
dence of HIV infection, indicating an H1V epidemic among IDUs that
has essentially been reversed. 127 To date, this study represents some of
the most compelling evidence in favor of SEPs, prompting New York
City health officials to launch an expanded syringe access initiative
involving pharmacists and registered physicians who are actively pre-
scribing syringes to IDUs.
In contrast to the above findings, two studies have not found SEPs
to have a protective effect on the risk of acquiring HIV infection. In
1997, an outbreak of HIV infection was described among IDUs in Van-
couver, Canada, despite the existence of a high volume SEP that had
been introduced early.1 28 In Montreal, Canada, SEP attendees were
reported to have higher HIV incidence rates than non-attendees. 29
Both studies fanned the flames of controversy surrounding SEP effec-
tiveness in the United States. However, in Canada these data were in-
terpreted as an indication that SEPs alone may be insufficient for
124. Strathdee & Vlahov, supra note 9, at 3 (citations omitted).
125. Alex Wodak & Peter Lurie, A Tale of Two Countries: Attempts to Control HIV in Austra-
lia and the United States, J. DRUG ISSUES 117, 118-19 (1997); Gerry V. Stimson, AIDS and
Injecting Drug Use in the United Kingdom, 1987-1993: The Policy Response and the Prevention of the
Epidemic, 41 Soc. ScL. & MED. 699, 711, 713 (1995); G.V. Stimson, Has the United Kingdom
Averted an Epidemic of HfV-1 Infection among Drug Injectors? 91 ADDICrION 1085, 1086 (1996);
Don C. Des Jarlais et al., Maintaining Low HIV Seroprevalence in Populations of Injecting Drug
Users, 274JAMA 1226, 1228-1229 (1995).
126. Susan F. Hurley et al., Effectiveness of Needle-Exchange Programmes for Prevention of HIV
Infection, 349 LANCET 1797, 1799 (1997).
127. Des Jarlais et al., supra note 121, at 1115-1116.
128. Strathdee et al., supra note 119, at 1340.
129. Julie Bruneau et al., High Rates of HIV Infection Among Injection Drug Users Participat-
ing in Needle Exchange Programs in Montreal: Results of a Cohort Study, 146 AM. J. EPIDEMIOLOGY
994, 996 (1997).
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meeting the need for sterile syringes among an IDU community, espe-
cially in settings where frequent cocaine injection predominates. '"" In
fact, it was estimated that both Vancouver and Montreal would need
to more than triple the number of syringes being exchanged to meet
the public health goal of a sterile syringe for every injection.'13 An-
other study that failed to find a protective effect of SEPs on HBV and
HCV infection was reported by Hagan and colleagues in Seattle.3-2
This study again prompted concerns from policy makers and scientists
that the science surrounding SEP effectiveness suffered from method-
ological shortcomings. 33
To some extent, methodological concerns are valid, since evalua-
tions of SEPs typically rely on observational study designs, which are
inherently prone to bias. For example, recent analyses have shown
that in many cities, SEPs attract high risk IDUs.1 34 Such self-selection
is not unexpected, nor even undesirable, given that most SEPs func-
tion as low threshold interventions. 13 5 These selection factors may ex-
plain why cities such as Montreal and Vancouver have observed higher
HIV seroconversion (development of antibodies in blood serum in re-
130. See Martin T. Schechter et al., Do Needle Exchange Programmes Increase the Spread of
HIVAmong Injection Drug Users?: An Investigation of the Vancouver Outbreak, 13 AIDS F45, F50
(1999); see Strathdee et al., supra note 119, at 1343-1344; Evan Wood et al., Factors Associ-
ated with Persistent High-Risk Syringe Sharing in the Presence of an Established Needle Exchange
Programme, 16 AIDS 941, 942 (2002).
131. See Robert S. Remis et al., Enough Sterile Syringes to Prevent HIV Transmission Among
Injection Drug Users in Montreal?, 18J. AcQuIRED IMMUNE DEFICIENCY SYNDROMES & HUMAN
RETROVIROLOGY S57, 858 (Supp. 1 1998); Strathdee et al., supra note 9.
132. Holly Hagan et al., Syringe Exchange and Risk of Infection with Hepatitis B and C Vi-
ruses, 149 AM. J. EPIDEMIOLOGY 203, 212 (1999) [hereinafter Hagan et al., Syringe Exchange].
But see Holly Hagan et al., Reduced Risk of Hepatitis B and Hepatitis C Among Injection Drug
Users in the Tacoma Syringe Exchange Program, 85 AM. J. PUB. HEALTH 1531, 1536 (1995)
[hereinafter Hagan et al., Reduced Risk].
133. See Roel A. Coutinho, Needle Exchange, Pragmatism, and Moralism, 90 AM. J. PUB.
HEALTH 1387, 1388 (2000); see also A.R. Moss, Epidemiology and the Politics of Needle Exchange,
90 AM. .. PUB. HEALTH 1385, 1386 (2000).
134. Judith A. Hahn et al., Who Uses Needle Exchange? A Study of Injection Drug Users in
Treatment in San Francisco, 1989-1990, 15 J. ACQUIRED IMMUNE DEFICIENCY SYNDROMES &
HUMAN RETROVIROLOGY 157, 162 (1997); Bruneau et al., supra note 129, at 996; David
Vlahov et al., Reductions in High-Risk Drug Use Behaviors Among Participants in the Baltimore
Needle Exchange Program, 16 J. ACQUIRED IMMUNE DEFICIENCY SYNDROMES & HUMAN RE-
TROVIROLOGY 400, 403-404 (1997); Chris P. Archibald et al., Factors Associated with Frequent
Needle Exchange Program Attendance in Injection Drug Users in Vancouver, Canada, 17 J. Ac-
QUIRED IMMUNE DEFICIENCY SYNDROMES & HUMAN RETROVIROLOGY 160, 162-163 (1998). See
generally Schechter et al., supra note 130, at F47, F50 (citing many other factors that make
IDUs at high risk for HIV infection).
135. Ernest Drucker et al., Measuring Harm Reduction: The Effects of Needle and Syringe
Exchange Programs and Methadone Maintenance on the Ecology of H1V, 12 AIDS S217, S220
(Supp. A 1998).
Summer 2003]
UNIVERSITY OF SAN FRANCISCO LAW REVIEW
sponse to infection) rates among SEP attendees compared to non-at-
tendees.13 6 In such settings, IDUs who subsequently begin attending a
SEP may have a higher risk of H1V seroconversion before ever attend-
ing the program.137 This has been clearly shown in San Francisco,
where IDUs who later began attending SEPs had higher HJV inci-
dence rates than those who never attended. 3s More recently in Van-
couver, the number of HIV seroconversions observed among frequent
versus infrequent SEP attendees could be predicted solely on the basis
of their higher baseline risk profile.' '19 These findings suggest that se-
lection factors could entirely explain observed disparities in HIV inci-
dence rates based on SEP attendance. Despite these limitations, the
majority of observational studies have consistently shown a protective
effect of SEPs on rates of needle sharing and HIV incidence. These
data lend strong support to the contention that SEPs can effectively
reduce the risk of blood borne diseases, especially when they operate
within the context of a comprehensive program including other forms
of syringe access. 141
Studies have also been conducted about the cost-effectiveness of
various syringe access programs. A recent study of seven SEPs in New
York reported a cost-effectiveness ratio of $20,947 per HIV infection
averted, suggesting that SEPs are both cost effective and cost saving. 14 1
A national policy of funding SEPs, pharmacy sales, and syringe dispo-
sal in the United States was estimated to cost $34,278 per HIV infec-
tion averted, which is well below the lifetime costs of treating an
individual's HIV infection. 14 2 Lurie and colleagues estimated the cost
per syringe distributed for five syringe distribution strategies: SEP, a
136. See Catherine M. Lowndes & Michael Alary, High Rates of HIV Infection Among Injec-
tion Drug Users Participating in Needle Exchange Programs in Montreal: Results of a Cohort Study,
148 Am.J. EPIDEMIOLOGY 713, 713 (1998) (letter to ed.); see also Schechter et al., supra note
130, at F50.
137. P. Lurie, Invited Commentary: LeMystereDeMontreal, 146 AM.J. EPIDEMIOLOGY 1003,
1004 (1997); Lowndes & Alary, supra note 136, at 713; Hahn et al., supra note 134, at 157.
138. Hahn et al., supra note 134, at 162.
139. See Schechter, et al., supra note 130, at F47.
140. E.J.C. van Ameijden et al., Risk Factors for the Transition from Noninjection to Injection
Drug Use and Accompanying AIDS Risk Behavior in a Cohort of Drug Users, 139 AM.J. EPIDEMIOL-
OGY 1153 (1994); Hagan et al., Reduced Risk, supra note 132, at 1536; Don C. DesJarlais et
al., HIVIncidence AmongInjecting Drug Users in Ner York City Syringe Exchange Programmes, 348
LANCET 987, 990 (1996); see Vlahov et al., supra note 134, at 405.
141. Franklin N. Laufer, Cost-Effectiveness of Syringe Exchange as an HlVPrevention Strategy,
28J. ACQUIRED IMMUNE DEFICIENCY SYNDROMES 273, 276 (2001).
142. David R. Holtgrave et al., Cost and Cost-Effectiveness of Increasing Access to Sterile Syr-
inges and Needles as an HIVPrevention Intervention in the United States, 18J. ACQUIRED IMMUNE
DEFICIENCY SYNDROMES & HUMAN RETROVIROLOGY S133, S136 (Supp. 1 1998).
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pharmacy-based SEP, free pharmacy distribution of pharmacy kits,
sale of such pharmacy kits to IDUs, and sale of syringes in pharma-
cies. 141 In this study, the cost per syringe was $0.97 for the SEP, $0.37
for the pharmacy-based SEP, $0.64 for pharmacy kit distribution,
$0.43 for pharmacy kit sale, and $0.15 for syringe sale. The total an-
nual cost of providing 50% of the syringes needed for a single syringe
for every injection ranged from $6 to $40 million for New York City,
from $1 to $6 million for San Francisco, and from $30,000 to $200,000
for Dayton, Ohio. The annual HIV seroconversion rate for the pro-
gram to be cost-neutral compared with the cost of medical treatment
for HIV injections was 2.1% for the SEP, 0.8% for the pharmacy SEP,
1.4% for pharmacy kit distribution, 0.9% for pharmacy kit sale, and
0.3% for syringe sales. 144
This study suggests that all five strategies could distribute syringes
at relatively low unit costs; however, SEPs would be the most expensive
and syringe sales would be the cheapest. At annual seroconversion
rates exceeding 2.1%, all strategies are likely to be cost-saving to soci-
ety. This point is borne out in a report issued in 2002 by the Australian
Department of Health and Ageing. The report concluded that Austra-
lia's $83 million investment in needle-exchange programs from 1990
to 2000 returned between $1.3 billion and $4.2 billion in avoided
costs.' 45 Given these results, it is clear United States policies restricting
syringe access at the federal and state levels have placed serious limits
on the ability to provide a sterile syringe for every injection. Legisla-
tion governing SEP funding and operation clearly undermine their
effectiveness, and could even contribute to a lack of measurable bene-
fit. Yet even in cities where SEPs are legal, there are fiscal and legisla-
tive restrictions on their hours of operation, staffing, and number of
syringes exchanged per visit; few SEPs offer true 24-hour coverage.
Beyond SEPs, state deregulation laws can persist in limiting the
purchase of more than ten syringes without a prescription (e.g., Con-
necticut), and pharmacy regulations can deter drug users from suc-
cessfully purchasing syringes over the counter.
Achieving and sustaining adequate syringe coverage in a commu-
nity will certainly require that restrictive policies do not limit access;
143. Peter Lurie et al., An Economic Analysis of Needle Exchange and Pharmacy-Based Pro-
grams to Increase Sterile Syringe Availability for Injection Drug Users, 18 J. ACQUIRED IMMUNE
DEFICIENCY SYNDROMES & HUMAN RETROVIROLOGY S126, S129 (Supp. 1 1998).
144. Id. at S128-130.
145. COMMONWEALTH DEPARTMENT OF HEALTH AND AGEING, RETURN ON INVESTMENT ON
NEEDLE AND SYRINGE PROGRAMS IN AUSTRALIA (2002), available at http://
www.health.gov.au/pubhlth/publicat/document/roireport.pdf.
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however, to achieve the goal of a sterile syringe for every injection, the
international literature indicates that diversification of syringe sources
and other interventions will be needed. 146
Summary. Evaluations of syringe access policies elsewhere in the
world have generally found them to be effective in reducing HIV
transmission without causing increases in drug use or other negative
effects. Studies in Vancouver and Montreal found that SEPs had no
protective effect; although these studies have been widely invoked by
SEP opponents, the consensus among SEP researchers (including the
authors of the studies) is that SEPs alone may not be sufficient to re-
verse the health effects of frequent, high risk injection. Cost-effective-
ness analyses have generally found that syringe access interventions do
produce a net benefit for society.
C. Evidence of Negative Effects of Policies to Improve Syringe
Access
From a policy perspective, attention has focused on whether or
not increased syringe access is associated with increases in drug use,
crime, or the number of discarded needles on the street. Once again,
the available research to date has focused almost entirely on these is-
sues in relation to SEPs.
Studies have consistently shown that SEPs are not associated with
increases in drug use. In Amsterdam, van Ameijden and colleagues
found that the introduction of a SEP was not associated with a de-
crease in the median age of initiation of injection. 147 The frequency of
injection drug use among IDUs attending SEPs in Baltimore did not
increase after a SEP was introduced. 48
The possibility that SEPs send adolescents a "mixed message" that
contradicts anti-drug messages and condones illicit drug use has been
cited as an important reason for maintaining a Congressional ban on
federal funding of SEPs in the United States.' 49 Yet in a survey of high
146. Strathdee & Vlahov, supra note 9, at 6.
147. See generally van Ameijden et al., supra note 140, at 1153; see also Ernst C. Buning,
Effects of Amsterdam Needle and Syringe Exchange, 26 INT'L J. THE ADDICrIONS 1303, 1307
(1991) (reporting no increase in drug use had been observed and rise in average age of
drug user occurred in Amsterdam).
148. Vlahov et al., supra note 134, at 403.
149. Congressman Bob Goodlatte, Representing Virginia's Sixth District, Send the Right
Message to Our Children: Just Say NO to Free Needles for Drug Addicts! (February 4, 1999) (Letter
to the Congress of the United States of America, from Bob Goodlatte, Dick Armey & Todd
Tiahrt) available at http://www.house.gov/goodlatte/needledearcl.htm. See generally David
E. Rogers & June E. Osborn, AIDS Policy: Two Divisive Issues, 270 JAMA 494, 495 (1993).
[Vol. 37
SYRINGE ACCESS
school adolescents in Baltimore, the majority of adolescents did not
perceive that seeing drug. users utilize SEPs promotes illicit drug
use.150 In fact, almost half perceived seeing drug users utilize SEPs as
actually deterring illicit drug use. To, our knowledge, the only other
study to examine the effect of SEPs on attitudes of youth toward drug
use was conducted by Friedman and colleagues in Bushwick, New
York. In this study, only 7% of adolescents and young adults surveyed
were aware that a SEP was operating in their vicinity. The authors con-
cluded that a SEP was unlikely to have had any effect on drug use
decision-making among the youth in the area, given the low level of
awareness of the existence of the program. 5 1 Taken together, these
findings do not support the concerns that SEPs promote acceptance
of drug use among youth.
One of the most enduring community concerns is that SEPs
could attract IDUs to congregate'in their neighborhoods, thereby in-
creasing crime rates. In a review of 16 SEPs, Lurie and colleagues 152
reported no evidence that SEPs were associated with increased crime.
This report, however, accounted only for specific crimes that were
likely to be drug-related and did not compare crime rates in terms of
proximity to the SEPs. More recently, Marx and colleagues' 53 com-
pared arrest rates in SEP areas against non-SEP .areas in Baltimore,
before and after the program was introduced. over a fifteen month
period. Four types of arrest categories were studied (drug possession,
economically motivated offenses, resistance to police, and violent of-
fenses). In all cases, there was no significant increase in arrest rates in
areas near SEPs compared to other regions in the city, suggesting that
at least in this setting, a SEP had no influence on crime rates., 54 The
extent to which a SEP is associated with an increase in violent crime
has also been examined in Harlem, New York. Here, a detailed analy-
sis found no relationship between reports of robberies or assaults and
the proximity to local SEPs, suggesting that SEPs do not cause an in-
crease of violence in their vicinity. 15 5
150. Melissa A. Marx et al., Impact of Needle Exchange Programs on Adolescent Perceptions
About Illicit Drug Use, 5 AIDS AND BEHAVIOR 379, 382 (2001).
151. See S.R. Friedman et al., The Message Not Heard: Myth and Reality in Discussions About
Syringe Exchange, 13 AIDS 738, 739 (1999).
152. LURIE ET AL., supra note 10.
153. Melissa A. Marx et al., Trends in Crime and the Introduction of a Needle Exchange Pro-
gram, 90 AM. J. PuB. HEALTH 1933 (2000).
154. Id. at 1934-1935.
155. Sandro Galea et al., Needle Exchange Programs and Experience of Violence in an Inner
City Neighborhood, 28J. ACQUIRED IMMUNE DEFICIENCY SYNDROMES 282, 286-287 (2001).
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Researchers have also examined whether SEPs are associated with
an increased number of discarded needles on the street. An early
study by Oliver suggested no such increase. 156 A more detailed study
that estimated the quantity and geographic distribution of discarded
needles on the streets of Baltimore, Maryland two years after the SEP
opened found a significant decline in the overall quantity of discarded
needles relative to drug vials and bottles. 5 7 The mean number of
needles per 100 trash items per block was 2.42 before the NEP opened
and 1.30 two years later. These data suggest that this SEP did not in-
crease the number or distribution of discarded needles, and in fact
was likely to have reduced the number of discarded needles that could
lead to community needle stick injuries. Although the above data are
largely restricted to Baltimore, to date there appears to be no pub-
lished evidence or even a body of anecdotal reports that enhanced
syringe access has negative societal effects.
There is equally limited evidence of a possible positive effect of
syringe possession legalization. At least one study has documented
that urban police officers in at least some areas suffer a considerable
number of needle-stick injuries in the course of pat-downs and
searches. 5 8 Groseclose and colleagues, in an evaluation of the effects
of syringe deregulation in Connecticut, found that reported needle-
stick injuries among police declined substantially in the six-month pe-
riod following the new law.159 In theory at least, decriminalizing syr-
inge possession could make IDUs more willing to warn police officers
of their possession of a syringe, just as it would be expected to make
IDUs generally more willing to safely dispose of syringes.
Summary. The research consistently supports the conclusion that
increased syringe access does not promote drug use or increase crime
or the volume of improperly discarded needles in the community.
D. Limitations of Existing Research on Syringe Access Policies
The majority of the published studies focus on evaluations of
SEPs; there is a paucity of data investigating outcomes related to other
156. Kathy J. Oliver et al., Impact of a Needle Exchange Program on Potentially Infectious
Syringes in Public Places, 5 J. ACQUIRED IMMUNE DEFICIENCY SYNDROMES 534 (1992).
157. Meg C. Doherty et al.,The Effect of a Needle Exchange Program on Numbers of Discarded
Needles: A 2-Year Follow-Up, 90 AM. J. PUB. HEAurH 936, 937-938 (2000).
158. John Lorentz et al., Occupational Needlestick Injuries in a Metropolitan Police Force, 18
AM . J. PREVENTIVE MED. 146, 147 (2000).
159. Samuel L. Groseclose et al., Impact of Increased Legal Access to Needles and Syringes on
Practices of Injecting-Drug Users and Police Officers-Connecticut, 1992-1993, 10J. ACQUIRED IM-
MUNE DEFICIENCY SYNDROMES & HUMAN RETROVIROLOGY 82, 83, 87 (1995).
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forms of syringe access, such as pharmacies, physician prescription,
and syringe vending machines. The small amount of published re-
search in this area may reflect the fact that the importance of alter-
nate syringe sources in achieving sterile syringe coverage among IDUs
has only recently been recognized. Similarly, studies examining behav-
ioral, societal, and health effects of deregulation of prescription, para-
phernalia or possession laws, and pharmacy sales are sparse. The latter
studies are rare because they require a change in legislation or phar-
macy regulations in order to create the conditions for a "natural
experiment."
Even among studies of SEP effectiveness, an overriding problem
has been the lack of a formal evaluation component that includes bio-
logic outcomes, such as HIV incidence. Longitudinal studies are ideal
for conducting such investigations, but these studies are costly and
time consuming. In most cities, HIV incidence rates are approxi-
mately 2% per year, limiting the ability to make inferences based on
HIV incidence rates in the absence of a very large sample size. As a
consequence, much of the existing data relies on behavioral surro-
gates, such as reports of needle sharing behavior and syringe ex-
change attendance, which are prone to socially desirable responding
(i.e., giving the response that the respondent believes others would
approve of). However, there is evidence to suggest that self-reports of
IDUs' behaviors are reasonably valid.' 60 In fact, a recent report sug-
gests that socially desirable responding may lead to an underestima-
tion of the protective effect of SEPs by as much as 20%.161
The ideal study design to examine whether or not providing ster-
ile syringes to IDUs reduces the risk of blood borne disease without
promoting negative societal effects would be a randomized clinical
trial of individuals in communities that have access or no access to
sterile syringes. However, a reasonable argument can be made that
such a design is unethical, since the majority of the international liter-
ature supports a protective effect of sterile syringe access on rates of
blood borne disease. To deny some members of a community access
to an intervention that is known to save their lives would certainly be
accused of violating prevailing ethical standards. Randomization of
160. James C. Anthony et al., Self-Reported Interview Data for a Study of HIV-1 Infection
Among Intravenous Drug Users: Description of Methods and Preliminary Evidence on Validity, 21 J.
DRUG ISSUES 739, 740 (1991).
161. Mahboobeh Safaeian et al., Validity of Self-Reported Needle Exchange Attendance Among
Injection Drug Users: Implications for Program Evaluation, 155 Am. J. EPIDEMIOLOGY 169, 173
(2002).
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different communities rather than individuals with access to different
syringe sources may circumvent these ethical concerns. This approach
is not generally feasible in most settings, though, since local drug
scenes are highly variable. However, in Alaska, a study of data from a
community-based randomized trial of SEP versus pharmacy access to
syringes is pending. 16 2
Given the lack of data on syringe access outcomes from interven-
tion trials, there is likely to be a continued reliance on observational
studies (i.e., non-experimental study designs) to examine the effec-
tiveness of SEP, pharmacy access, and deregulation. As a conse-
quence, a major methodological hurdle is the lack of an appropriate
comparison group through which valid inferences about risk reduc-
tion reasonably can be made. In deregulation studies, one approach
has been to compare risk behaviors and health outcomes in the pe-
riod prior to the regulation change, compared to the period after-
ward. This approach is limited by the possibility that other secular
changes may have occurred during this period which may bias results.
National studies using multiple data sets over time may help to un-
cover trends, but this type of ecological approach cannot be used to
make inferences at the individual level.
Even in cases where virtually all IDUs .in a given setting have uti-
lized a given syringe source, -it is still possible to -undertake process
evaluation to determine which combination of services or compo-
nents of SEPs are most or least effective. This is especially needed
since SEPs vary enormously in the range of services they provide,
hours of operation, and local regulations, including factors governed
by their legal status. The lack of comparability across programs has
hampered evaluation studies and limited .the ability to generalize
about specific findings.
Unfortunately, very few studies have evaluated programmatic
characteristics of SEPs. This research can help to determine which
kinds of services will maximize sterile syringe coverage in -a commu-
nity. 163 One such example is the finding that mobile SEPs are likely to
attract higher risk IDUs than fixed site programs. 6 4 Without taking
into account the various components of SEPs and their direct and in-
162. Interview with Dr. Dennis Fisher (2001).
163. Bastos & Strathdee, supra note 122, at 1772, 1779.
164. Elise D. Riley et al., Comparing New Participants of a Mobile Versus a Pharmacy-Based
Needle Exchange Program, 24 J. ACQUIRED IMMUNE DEFICIENcY SYNDROMES & HUMAN RE-
TROVIROLOGY 57, 58-59 (2000).
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direct effects, observational studies attempting to evaluate SEPs will
likely continue to produce conflicting findings.
In light of the selection factors that are inherent in observational
studies, there is a need for 'more sophisticated analysesthat take into
account these biases, lest they underestimate or mask a protective ef-
fect of the intervention, or create spurious associations. In evaluations
of SEPs, for example, most studies have merely employed dichoto-
mous categorizations (e.g., SEP attendees versus non-attendees, fre-
quent versus infrequent attendees),. This simplistic approach
overlooks the fact that. non-attendees may have entirely met their
need for sterile syringes through other means. A recent analysis of
SEP attendees in Amsterdam-a city where sterile syringes are readily
available through pharmacies-found, that irregular SEP attendees
had a higher risk of HIV seroconversion than non- or frequent at-
tendees.165 These authors concluded that irregular SEP attendees had
the least exposure to sterile injection equipment and consistent pre-
vention messages, which placed them at higher risk of infection. Some
authors have suggested that propensity scores or hierarchical model-
ing may offer viable solutions to "adjust" for the selection bias that can
compromise the validity of research findings.
Beyond factors relating -to frequency of utilization of a specific
syringe source and the volume of syringes obtained, program effec-
tiveness can vary depending on the circulation time of contaminated
syringes in the community166 and whether syringes are obtained di-
rectly or through intermediaries. In the case of SEPs, this phenome-
non is referred to as secondary exchange. While secondary exchange
provides extended coverage of SEPs to IDUs in the broader commu-
nity, its recipients typically do not receive H1V/AIDS education, coun-
seling, or referrals to drug treatment that could have been received
had they attended the SEP themselves. 1 67 To date, research is lacking
on these indirect effects of SEPs, which could. prove to be just as im-
portant as the direct effect on SEP attendees. Furthermore, pharma-
cies may serve as an excellent yenue for providing health education to
IDUs; however, thus far they appear to, have been grossly under-uti-
lized in this, regard.
165. See van Ameijden & Coutinho, supra note 121, at 630.
166. Edward H. Kaplan, Probability Models of Needle Exchange, 43 OPERATIONS RES. 558,
561-562 (1995); E.H. Kaplan, A. Method for Evaluating Needle Exchange Programmes, 13 STAT.
MED. 2179, 2181 (1994)..
167. Valente et al., supra note 73, at 91.
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No matter what method is used to study syringe access, it is cru-
cial to devote more attention to the social context of risk. This context
includes elements ranging from IDUs' sexual relationships, 168 to the
socioeconomic characteristics of the communities where they live.169
Of particular importance, as our review of the data has illustrated, is
the role of law and law enforcement practices on IDU behavior and
the risk of disease. Ethnographic research clearly shows that IDUs'
ability to obtain sterile injection equipment, to carry it, and to inject
in a sterile fashion is strongly influenced by the extent to which they
fear police interference. 17°1 Research that fails to address this key de-
terminant of IDU health will not provide an adequate understanding
of necessary changes in policy and law enforcement practices, or of
effective means for individual IDUs to reduce their risk.
Research on needle access, risk environments, and health among
IDUs may also face increasing political barriers in the United States.
Because syringe access is a controversial issue, fear of political conse-
quences may deter funders from supporting research studying syringe
access and its effects. It has been reported in the press that staff at the
National Institutes of Health, the nation's largest funder of health re-
search, have been warning applicants to avoid using terms such as
"needle exchange" in grant applications. It is said this is necessary to
reduce the risk of unwanted scrutiny from congressional staffers who
regularly search NIH data-bases for politically sensitive projects. 171
Stories like these can deter researchers from undertaking work in the
area.
Summary. The available data is sufficient to justify a public policy
of greater syringe access for IDUs, but the literature has limitations, at
least some of which can be addressed in future research. One correct-
able deficiency is the lack of data on measures other than SEPs, which
will be remedied as current studies on the implementation of recent
168. See generally Tim Rhodes, The 'Risk Environment ' A Framework for Understanding and
Reducing Drug-Related Harm, 13 IrNT'L J. DRUG POL'y 85 (2002); see also Tim Rhodes et al.,
Sex, Drugs, Intervention, and Research: From the Individual to the Social, 31 SUBSTANCE USE &
MISUSE 375 (1996).
169. See Robert Sampson &Jeffrey Morenoff, Public Health and Safety in Context: Lessons
from Community-Level Theory on Social Capital, in PROMOTING HEALTH: INTERVENTION STRATE-
GIES FROM SOCIAL AND BEHAVIORAL RESEARCH 366, 367 (Brian D. Smedley & S. Leonard
Syme eds., 2000).
170. Koester, supra note 103, at 292; Bourgois, supra note 103, at 2336; see Kim Blanken-
ship & Stephen Koester, Criminal Law, Policing Policy, and HIV Risk in Female Street Sex Work-
ers and Injection Drug Users, 30J. L. MED. & ETHICS 548, 551-52 (2002).
171. See Erica Goode, Certain Words Can Trip Up AIDS Grants, Scientists Say, N.Y. Times,
Apr. 18, 2003, at A10.
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interventions are completed. 172 Enhancing the use of biologic out-
come measures can reduce the distortions of self-reported behavior.
Because randomized controlled studies, often referred to as the gold-
standard in other areas of biomedical research, are difficult and ar-
guably unethical to use in the syringe access context, observational
studies will continue to be the main method of studying syringe ac-
cess. These may be improved by, among other steps, incorporating
more scrutiny of program factors (such as hours of operation, loca-
tion, etc.) and by the development of more sophisticated analytic ap-
proaches. It will be important to ensure, as much as reasonably
possible, that research decisions are not subject to political
interference.
V. Analysis of Public Opinion, Ethics, and Politics
Lawfulness and effectiveness are only part of the syringe access
policy problem. It remains critically important to address at least three
additional, and inter-related, questions: 1) does enhanced syringe ac-
cess have an adequate level of public support, 2) is the policy ethically
appropriate, and 3) is the policy politically feasible.
A. Public Opinion
Public policy is influenced by public opinion. Public support for a
given policy, however, does not always produce immediate action by
policy-makers. This disconnect between public opinion and public
policy may be more likely to occur where, as with syringe access poli-
cies, public opinion is relatively malleable. Also, opponents of a given
public health policy sometimes feel more strongly about the issue
than do supporters. There are many other examples of this phenome-
non. For example, solid majorities of the American public have long
supported making it more difficult to obtain and carry handguns. 173
Yet progress in enacting gun violence prevention laws has been rela-
tively slow.174
172. See G.S. Birkhead et al., New York State's Expanded Syringe Access Demonstration
Program (ESAP): A Statewide Intervention to Prevent HIV/AIDS, Paper presented at X!V
International AIDS Conference (Barcelona, Spain, 2002); S.J. Klein et al., What Do Pharmacists
Think About New York State's New Nonprescription Syringe Sale Program? Results of a Survey, 78 J.
URn. HEALTH 679 (2001).
173. See Stephen P. Teret et al., Support for New Policies to Regulate Firearms: Results of Two
National Surveys, 339 NEw ENG. J. MED. 813, 815-816 (1998).
174. See generally Jon S. Vernick & Stephen P. Teret, A Public Health Approach to Regulat-
ing Firearms as Consumer Products, 148 U. PA. L. REv. 1193 (2000).
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To assess the possible role of public opinion in shaping present
and future syringe access policies, we undertook a systematic search
for all reported national surveys. Several different methods were em-
ployed. The Roper Center for Public Opinion Research at the Univer-
sity of Connecticut acts as a repository for public opinion polls on all
topics. We performed a search of its database for any survey question
with the words "needle," "syringe," or "drug paraphernalia." We re-
viewed each question and eliminated those that: 1) were unrelated to
syringe access programs, 2) were from polls that were not national in
scope, or 3) were tangential to basic support or opposition to these
polices. A total of 21 different questions from 11 different polls con-
ducted from 1987 to 1999 were identified in this manner. These are
summarized in Table XI.175 To allow the reader to better assess how
question wording can influence poll results, we have included the full
text of each question in Table XI.
In addition, we conducted a Lexis/Nexis search of newspaper ar-
ticles for references to national polls since 1995. This search yielded
one additional poll, conducted by the Kaiser Family Foundation in
late 2000, and released to the public in June 2001.176 As the most re-
cent poll we identified, its findings are summarized here. That poll
included 4 questions relevant to syringe access by IDUs. Fifty-eight
percent of respondents reported that "to help stop the spread of HIV"
they would favor "needle exchange programs which offer clean need-
les to IV drug users in exchange for used needles." Nearly identical
proportions also supported changing federal law to permit "state and
local governments [to] decide for themselves whether to use their fed-
eral funds for needle exchange programs"(60%), 'allowing IV drug
users to purchase clean needles from a licensed pharmacist" (61%),
and "allowing doctors and physicians to provide V drug users with a
prescription for clean needles" (60%).177 For each of these questions,
there were only modest, if any, differences in support or opposition
among various gender, race, or age groups.
As Table XI demonstrates, there is no clear national consensus
on the desirability of syringe access programs. Over time, support has
ranged from 29% to 73%. We were able to identify just two additional
175. Roper Center for Public Opinion Research, On-line Database of Poll Questions, at
http://library.dialog.com/bluesheets/html/b10468.html.
176. HENRYJ. KAISER FAMILY FOUNDATION, THE AIDS EPIDEMIC AT 20 YEARS: THE VIEW
FROM AMERICA, at http://www.kff.org/content/2001/3026/aids20rpt.pdf (last accessed
December 14, 2001).
177. Id.
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questions querying public support for other syringe access policies,
both in a 1994 poll sponsored by an organization called Drug Strate-
gies. In that poll, just 37% of respondents favored "allowing drug
users to buy clean needles without prescriptions from pharmacies";
40% favored "removing criminal penalties for the simple possession of
needles and syringes."
As is often the case with public opinion polls, however, precise
wording of the question can strongly affect observed public support or
opposition. For example, in both 1998 and 1999, the Family Research
Council asked questions about support for syringe exchange pro-
grams. In the 1998 question, users of SEPs were referred to as "those
addicted to illegal drugs." In 1999, the question was identical, except
that users of SEPs were now described as "drug addicts." Support in
1998 was 43%; in 1999, it had fallen to 34%. In an earlier 1997 poll
sponsored by the Kaiser Family Foundation, the phrase "IV (intrave-
nous) drug users" was employed, and 64% of respondents favored
SEPs.
Other differences in question design can also be important. For
example, in the same Kaiser poll, a separate question using what are
called "permissive statements" was asked of a different subset of re-
spondents. Respondents were told that "some people favor offering
clean needles . . . to reduce the spread of HIV; others oppose ex-
change programs because they ... send the message that it's OK to
use illegal drugs." With these permissive statements, support was sub-
stantially lower, just 48%. However, even from this lower baseline of
support, when respondents are then told that scientific evidence sug-
gests that SEPs are effective, support again increases to a total of 60%.
Clearly, levels of national support for SEPs are not very stable.
The biases of the organizations sponsoring the polls may also af-
fect the outcomes of interest. For example, the Family Research Coun-
cil describes itself as "champion [ing] marriage and family as the
foundation of civilization, the seedbed of virtue, and the wellspring of
society. 1 78 By comparison, the Kaiser Family Foundation is an "inde-
pendent philanthropy focusing on the major health care issues facing
the nation." 179 The Family Research Council, therefore is likely to
view syringe access interventions through the lens of its "family values"
mission, while Kaiser will pose the question as one primarily of health
178. FAMILY RESEARCH COUNCIL, FAMILY RESEARCH COUNCIL MISSION STATEMENT, at
http://www.frc.org/aboutfrc.cfm (last accessed December 14, 2001).
179. HENRYJ. KAISER FAMILY FOUNDATION, ABOUT THE HENRYJ. KAISER FAMILY FOUNDA-
"iON, at http://www.kff.org/docs/about (last accessed December 14, 2001).
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policy. These differences may be perceived (perhaps subtly) by re-
spondents. They are also likely to affect the context in which ques-
tions about syringe access policies are asked within the larger survey
instrument.
It can be very difficult to interpret the policy-impact of survey re-
search findings on topics that most respondents have probably not
carefully considered. Weak levels of support may simply mean that
many respondents do not fully understand the issue (or its scientific
basis), which cannot be explained effectively in a brief telephone in-
terview. Even if levels of national support are malleable, this may be
less relevant for some aspects of syringe access policy than for others.
Most SEPs are locally designed and implemented. In that sense, local
levels of support are probably far more important than national levels.
In addition, to the extent that many of these programs are privately
funded, governmental or public support may simply not be needed in
some places. However, national public opinion can obviously affect
willingness to provide state or federal funds for SEPs. Currently, fed-
eral funds may not be used to support SEPs.
Our results also suggest possible ways to increase public support
for syringe access interventions. It appears that linking syringe access
with broader drug policy is associated with lower levels of support. To
the extent that the "war on drugs" is seen as a moral crusade by some,
and a misguided failure by others, uncoupling syringe access from
drug policy has the potential to de-polarize the syringe access debate.
Similarly, describing syringe access interventions as health policy,
rather than drug control policy, may also increase support. Finally, a
public discourse that avoids the use of loaded terms, like "drug ad-
dicts" or 'junkies," may contribute to a more rational, less stigma-
driven assessment of syringe access by the public.
B. Bioethics Literature Regarding Syringe Access Policies
Despite the controversy surrounding syringe access policies, espe-
cially SEPs, there has been little scholarly effort devoted to analyzing
their bioethical implications. A comprehensive literature review, with
the invaluable assistance of the National Reference Center for
Bioethics literature at Georgetown University's Kennedy Institute of
Ethics, yielded just two journal articles whose primary focus was on the
ethics of SEPs. Many other articles include brief discussions of the so-
cietal or moral appropriateness of SEPs, often in the discussion sec-
tion of a more general article, but do not develop an explicit ethical
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basis for that conclusion. These are generally excluded from this
section.
The most comprehensive published effort to analyze the
bioethics of SEPs was by Loue, Lurie, and Lloyd in 1995.180 That arti-
cle employs a traditional bioethics framework, popularized by
Beauchamp and Childress.' 8 l That framework typically includes an
analysis of the following basic components: 1) nonmaleficence; 2) be-
neficence; 3) respect for persons; and 4) justice. Nonmaleficence re-
fers to the obligation to avoid intentionally harming others, while
beneficence includes affirmative actions designed to help others. Re-
spect for persons incorporates concepts of autonomy and informed
consent. Justice in this context implies fairness in treatment and an
appropriate distribution of benefits and burdens. Loue and colleagues
also add a discussion of utilitarianism. Utilitarianism focuses on the
consequences of actions in order to assess their "rightness." Right ac-
tions or policies will attempt to maximize good outcomes and mini-
mize bad ones.18 2
For Loue et al., the principle of beneficence is easily satisfied by
SEPs. SEPs reduce the risk of infection for individuals. For communi-
ties, the number of syringes discarded in public places is decreased.
Nonmaleficence is also satisfied where the SEP insulates users from
targeting by the police. Other potential harms to IDUs participating
in SEPs, such as the risk that drug use will be encouraged, can be
mitigated by referrals for drug treatment or counseling. SEPs exhibit
respect for persons when they encourage healthy decisions, lack any
form of compulsion to participate, and ensure the confidentiality of
the users. Finally, the principle of justice requires that society accept
the costs of SEPs, and not discriminate against IDUs. This is especially
important where society has chosen not to provide adequate drug
treatment resources in most communities.I 3 For Loue et al., SEPs are
also justified on utilitarian grounds. If properly designed and imple-
mented, they minimize harms to IDUs and the community.
The only other effort to systematically assess the ethical implica-
tions of SEPs was authored by Maura O'Brien in 1989, just one year
180. Sana Loue et al., Ethical Issues Raised by Needle Exchange Programs, 23 J.L. MED. &
ETHICS 382 (1995).
181. TOM L. BEAUCHAMP &JAMES F. CHILDRESS, PRINCIPLES OF BIOMEDICAL ETHICS (4th
ed. 1994).
182. Id.
183. Loue et al., supra note 180, 382-383.
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after the first SEP in the U.S. was instituted. 184 Employing a different
framework, O'Brien also concludes that SEPs are ethically justified.
The strength of her conclusion was limited, however, by the absence
of substantial effectiveness data at that early date.
Loue et al. also briefly discuss the ethics of physician prescription
and pharmacy sale of syringes, topics that Lazzarini addresses in sub-
stantially more detail.18 5 Lazzarini employs a variety of ethical princi-
ples and theories, but also focuses on the 4 traditional principles.
Regarding physician prescription of syringes, she notes that principles
of beneficence and respect for persons might seem to conflict. The
notion of autonomy inherent in respect for persons argues for physi-
cian prescription of syringes where that is the informed choice of an
IDU. But a "beneficent" physician might be concerned about facilitat-
ing an IDU's drug habit. Lazzarini concludes, however, that physician
prescription of syringes is ethically appropriate. She argues that the
principle of beneficence warrants both efforts to convince IDUs to
cease their drug use or enter treatment, and efforts to provide sterile
syringes for those IDUs who cannot or will not stop injecting drugs.
The few ethical analyses that have been done support the use of
SEPs and physician prescribing of syringes. However, based on the rel-
atively scant volume of literature, we wonder if the bioethics commu-
nity has devoted adequate attention to this issue. This is especially
surprising given the high levels of media and policy-maker attention
that syringe access policies have received. In particular, it does not
appear that bioethicists have devoted nearly as much attention to the
ethics of syringe access policy as they have to other aspects of the AIDS
epidemic, such as issues of patient screening or contact tracing. From
a policy perspective, greater participation by bioethicists and other
opinion leaders could affect both public opinion and the political fea-
sibility of some syringe access policies.
Another interesting feature of the SEP literature concerns re-
search ethics. A randomized, controlled trial of IDUs assigned to SEP
participation or non-participation has been deemed by many to be
ethically problematic. The concern is that, given the magnitude of re-
search suggesting that SEPs are beneficial, the research community no
longer has the necessary equipoise that would allow randomly exclud-
ing some IDUs from SEP participation. However, if one were per-
184. Maura O'Brien, Needle Exchange Programs: Ethical and Policy Issues, 4 AIDS & PUB.
POL'YJ. 75, 78 (1989).
185. Zita Lazzarini, An Analysis of Ethical Issues in Prescribing and Dispensing Syringes to
Injection Drug Users, 11 HEALTH MAIRIX 85, 95, 127 (2001).
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suaded by recent research suggesting that, at least in some
circumstances SEPs may not reduce seroconversion rates, this could
alter the bioethics landscape. Under those circumstances, random-
ized, controlled trials might be ethically permissible provided that the
control group had some other form of access to clean syringes.
Whether additional research, even some "gold-standard" clinical trial,
would affect the positions of opponents is a separate question.
C. Politics
We have previously described the history of SEPs in the United
States. This history has also been presented in greater detail by
others. 186 But there have been only limited efforts in the political sci-
ence or public health literature to systematically explore the politics
of syringe access policy. 187 Nevertheless, in our view, some features of
the structure of the political debate are apparent. We identify three
major themes in that debate: 1) disagreements about science, 2) con-
cerns about symbolism, and 3) differences in how the problem is
framed.
The available research is interpreted differently by syringe access
proponents and opponents. For example, SEP opponent Robert Ma-
ginnis writes: "Two compelling studies, published in 1997, found that
NEP participants were more likely to contract HIV than addicts who
don't use NEPs." 188 SEP proponents argue that these same studies
may have been influenced by selection bias. Proponents are also-more
likely to consider the totality of the scientific evidence supportive of
the benefits of SEPs. Disagreements about SEP science may also re-
flect different views about the appropriate course of action if there is
any scientific uncertainty. Some opponents of SEPs may believe that
SEPs should not be implemented if there is any doubt that they may
promote drug use. In addition, because SEPs have not been instituted
in all communities, opponents may be uncertain about the overall ef-
fect SEPs would have if more widely implemented. Unfortunately, the
absence of federal funding for both SEPs and SEP research creates a
feedback mechanism. The absence of federal funding makes large-
scale, well-designed studies much more difficult to conduct. And the
186. See Vlahov et al, supra note 17.
187. See, e.g., Moss, supra note 133; Coutinho, supra note 133.
188. R.L. Maginnis, Injecting Drug Use: A 2000 Overview, THE FAMILY RESEARCH COUNCIL
at http://www.frc.org (last accessed December 14, 2001) (copy on file with the University
of San Francisco Law Review).
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lack of the kind of effectiveness data that such studies might produce
helps to perpetuate and even reinforce the funding ban.
Other arguments are based not on disputes over science, but over
the symbolism of SEPs or other syringe access policies. Opponents ar-
gue that SEPs send a message that drug use is condoned, and under-
mine other anti-drug messages. Proponents generally respond with
some variation on the theme of harm reduction-that some IDUs will
not stop injecting illegal drugs despite anti-drug messages and that,
therefore, SEPs are an appropriate response. Interestingly, at least
one public opinion poll has sought to indirectly assess the persuasive-
ness of this argument. In a 1998 poll sponsored by the SEP opponents,
The Family Research Council, a plurality of respondents (46%)
thought that "government funded needle exchange programs" did
not "represent an official endorsement of drug use by the govern-
ment." Forty-one percent thought that SEPs would represent such an
endorsement.
Perhaps most important to understanding the politics of SEPs,
however, are differences in how opponents and proponents define
and frame the problem. Consistent with their concern about science
and symbolism, opponents view SEPs primarily through the lens of
drug policy, while proponents of SEPs generally define the problem as
one of disease prevention. Interestingly, this latter view may be gain-
ing currency with the public. In a 2001 poll sponsored by the Pew
Research Center, 1500 United States adults were asked a series of
questions about drug policy. When asked: "All in all, should drug use
be treated more like a crime or more like a disease?" 35% said "crime"
and 52% "disease." Attitudes were similarly divided in an analysis of
community responses to a 2000 California law making it easier for lo-
calities to sponsor SEPs. Among key stakeholders, police were most
likely to be opposed to SEPs, often describing them as likely to in-
crease crime by "facilitating drug use." By comparison, local public
health officials provided epidemiological data to policy-makers and
SEP advocates, suggesting a health perspective on the issue. Changing
police attitudes proved important to the ultimate success of SEPs in
some communities. 89
Resolving this problem-framing disjunction may be the most sig-
nificant challenge for SEP proponents. One possible strategy, already
189. Chris Collins et al., Syringe Exchange and AB 136: The Dynamics of Local Consideration
in 6 California Communities (2002) THE HENRY J. KAISER FAMILY FOUNDATION at http://
www.kff.org/content/2002/6018/AB 136%20Report.pdf (last accessed December 14,
2001).
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employed by scientists and some policy-makers, uses research to
demonstrate that SEPs do not harm drug control efforts. Another
strategy may be to argue that, in general, health issues should out-
weigh or trump possible drug control issues. The persuasiveness of
both arguments might be bolstered by reference to the experience of
European countries that have instituted SEPs without an increase in
drug use.
Of course, for some opponents, the decision is probably a simple
political one. They represent, or are influenced by, a constituent
group that has a particular cluster of positions, including opposition
to SEPs. 19°1 For those whose position is based on realpolitik, it is un-
likely that polling or other data will change minds.
VII. Recommendations for Policy
Were public health policy dictated purely by behavioral research
and cost-benefit analysis, unfettered syringe access would be part of
the response to prevent the spread of blood borne disease throughout
the United States and elsewhere. While the existing research base has
its limitations, the strong preponderance of the data and the experi-
ence of other countries leave little doubt that making sure IDUs can
obtain, carry, and use a sterile syringe for as many injections as possi-
ble can make a valuable contribution to controlling HIV among IDUs.
In considering this "ideal" policy, it is not particularly problem-
atic that the research supporting syringe access has limitations of both
methodology and scope. Nor is it significant that the goal of having
every IDU use a new sterile syringe for every injection is not likely to
be achieved anytime soon, even with completely unfettered syringe
access. Policy frequently proceeds faster than prevention science, and
necessarily so: perfect information is a luxury policy makers cannot
afford. Throughout public health and governance generally, policy-
makers must make reasoned judgments in response to problems
before all questions can be answered.
Syringe access is important, probably even necessary, but it is not
a panacea for the prevention of blood borne disease among IDUs and
their surrounding communities. In the ideal policy, formed and con-
tinuously updated based on new data, syringe access would be part of
a comprehensive set of medical and social interventions aimed at in-
creasing the uptake and success of drug treatment while reducing the
190. See Linda Rosenstock & Lore J. Lee, Attacks on Science: The Risks to Evidence-Based
Policy, 92 Am.J. PUB. HEALTH 14, 17 (2002).
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harmful health consequences of continuing drug use. For syringe ac-
cess to work for public health, it need not be 100 percent successful; it
just needs to increase the marginal use sufficiently to either cost effec-
tively reduce cases or create a sufficient level of safe use to reverse the
trend of the epidemic. In the ideal world, the effects and best prac-
tices of unfettered syringe access would continue to be studied, and
policy would be adapted accordingly.
In our distinctly non-Platonic world, health policy is not made
purely on the basis of science and expert reflection. Syringe access is a
contentious political issue and the public reaction to enhanced access
is mixed, even if not deeply felt. In this real world, the essential chal-
lenge for policy makers who credit the information public health pro-
fessionals provide is to decide where to draw the line between
effectiveness and political feasibility. Experience shows that the loca-
tion of this line can vary from state to state and even city to city. Our
review suggests the following conclusions.
1. Syringe Access Should Be Deregulated
Complete deregulation is the most desirable model to maximize
access to sterile syringes. Syringes are standard medical devices used
by millions of people on a daily basis. Apart from quality control, they
have been regulated only in so far as they are susceptible for use with
illegal drugs. Compared with other syringe access options, deregula-
tion allows distribution by the widest variety of means and outlets.
With restrictions repealed, syringes could be sold not only in pharma-
cies, but also convenience stores, groceries, and other accessible loca-
tions,' 91 or could be handed out without cost by public health and
community organizations. By removing all restrictions on syringe dis-
tribution, deregulation also eliminates legal barriers to syringe ex-
change. Deregulation takes possession almost entirely out of the
purview of law enforcement, making it legally safe for IDUs to have
sterile syringes at hand when they need them, and removing an im-
portant legal barrier to safe syringe disposal. It is a market-driven solu-
tion that leaves sellers and buyers free to make their own choices.
From the political point of view, it eliminates syringe access as a debat-
ing issue and gives public health agencies a free hand in crafting dis-
tribution programs that best serve the goal of disease prevention.
There is no evidence that unfettered access to sterile injection equip-
191. See Yolanda Obadia et al., Syringe Vending Machines for Injection Drug Users: An Exper-
iment in Marseille, France, 89 AM. J. PUB. HEALTH 1852 (1999).
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ment causes people to begin or increase drug use, or an increase in
the improper disposal of used syringes.
2. IDUs Should Not Be Subject to Arrest or Prosecution for
Possession of the Residue of Drugs Left in the Barrel of
a Used Syringe
The ability to obtain a syringe is not sufficient to minimize unsafe
syringe use among IDUs. IDUs must also be comfortable carrying the
syringe. Although not optimal, re-use of one's own syringe is prefera-
ble to sharing,, and it is necessary to retain a used syringe for proper
disposal at a syringe exchange or elsewhere. As the federal judge con-
cluded in Doe v. Bridgeport Police Department, 192 arresting drug users for
possessing a residual, trace amount of an illegal drug in the barrel of a
syringe is antithetical to a public policy favoring sterile injection and
proper disposal of used syringes. It is- unlikely that state drug posses-
sion laws would be rendered ineffective by raising the minimum quan-
tity of drugs necessary to ground a conviction. Although the ability to
make a stop or arrest based on probable cause to believe that a used
syringe contains drugs may be a tool of street law enforcement, a
health perspective suggests society pays a high price for its use. States
should revisit this issue. Regardless of the need for de minimis thresh-
olds for general drug control, it is possible to exempt such amounts
within syringes, or for law enforcement authorities to develop stan-
dard operating procedures that avoid stops, arrests, or prosecutions
based on drug residues in syringes.
3. Laws Governing SEPs Should Place a Minimum of Restrictions
on Their Manner of Operation
Deregulation does niot eliminate the need for the SEP as a public
health program. SEPs can provide a range of health and social services
that pharmacies and other retail outlets ordinarily cannot. With or
without deregulation, however, the best laws authorizing SEPs will be
those that set minimal restrictions on the manner in which the inter-
vention is conducted. Syringe exchange is a work in progress for pub-
lic health. Assessment data and day-to-day experience should continue
to be collected and digested into best practices, which SEPs should be
free to adopt as they become known. Rigid one-for-one exchange re-
quirements or caps on the number of syringes to be exchanged are
not consistent with research evidence even today, and restrictions gen-
192. 198 F.R.D. 325, 345 (D. Conn. 2001).
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erally are not consistent with the development of optimal practices. In
fact, limitations on SEP operations may inadvertently "stack the deck"
against the ability of these programs to prevent blood borne disease
transmission among IDUs.
4. The United States Should Develop a National Policy on the
Disposal of Household Sharps
Although there is no compelling reason to continue to regulate
distribution and possession of syringes, there is an unmistakable need
for a national policy for the disposal of medical sharps used outside
the health care system. An effective system could be developed and
funded within the private sector, or conducted by government, but
leadership and probably a legal mandate and some funding will be
required from government. In 2002, a Coalition for Safe Community
Needle Disposal was founded to spearhead development of disposal
solutions at the local, state, and national levels.' 93
5. Syringe Access Should Be Integrated into a Comprehensive
Approach to Reducing Drug Use and Its Health
Consequences
Improved access to sterile syringes can substantially reduce IDUs'
risks of acquiring and transmitting blood borne viral infections. It
should not, however, be seen as a free-standing intervention or strat-
egy. This review has focused on the role of syringe access in the behav-
ior of IDUs and the spread of blood borne disease, but syringe access
is only one factor in this complex social equation. Taking a broader
view of the spread of disease among IDUs, and the resources for
preventing it, the Centers for Disease. Control and Prevention (CDC)
and other leaders in HIV-prevention recommend a comprehensive
approach to prevention of blood borne infections among IDUs, their
sex partners and children. 94 Syringe access is an important compo-
nent of a comprehensive approach, but should be supported by other
interventions including substance abuse treatment, effective commu-
nity outreach to IDUs, drug and health services in correctional facili-
ties, strategies to prevent sexual. transmission of disease, HIV
counseling, testing and referral services for IDUs living with HIV, and
primary drug prevention. 9 5 CDC's recommendation is consistent
with the data we have reviewed on syringe access policies, both from a
193. See at http://www.safeneedledisposal.org/.
194. ACADEMY FOR EDUCATIONAL DEVELOPMENT, supra note 1.
195. Id.
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public health and a policy point of view. In health terms, it is clear
that many factors influence IDU risk behavior, and that better syringe
access can significantly reduce but not alone prevent the continued
spread of HIV. In political terms, an approach that places syringe ac-
cess in a larger effort to get people off drugs and to prevent them
from starting drug use in the first place emphasizes that harm reduc-
tion measures are not aimed at promoting drug use.
6. The Critical Importance of Properly Implementing Syringe
Access Policies Should Be Recognized and Addressed
There is frequently a gap between the way policies are intended
to work and the way they actually operate in practice.1 96 This imple-
mentation gap typically reflects a variety of factors, including unantici-
pated barriers, confusion about the policy's details, and often most
important, resistance to the policy among those who are intended to
be influenced by it or who must carry it out. In the case of syringe
access, the ultimate goal is to facilitate safe behavior among IDUs, but
a necessary precondition is participation in syringe exchange, phar-
macy access, physician prescription, or safe disposal schemes. Like-
wise, as the Doe v. Bridgeport and Roe v. City of New York cases
dramatically illustrate, the understanding and support of police and
prosecutors can be indispensable to the actual implementation of pol-
icies that enhance syringe access on paper. It is therefore not suffi-
cient to merely pass a syringe access law. Policy-makers should require
and fund an implementation support and evaluation process that in-
cludes education directed at consumers, pharmacists, other sellers,
and law enforcement officials, so that all the key players understand
the value of syringe access and their role in disease prevention. Re-
search on the impact of the new policy on attitudes and behaviors
among all the stakeholders is also crucial.
Conclusion
The data plainly support the view that syringe access and drug
possession laws and law enforcement practices influence how drug
users inject, whether they do so with a new syringe or not, and how
196. See, e.g.,JEFFREY L. PRESSMAN & AARON B. WILDAVSKY, IMI'LEMENTrATION (1973); JEF-
FREY PRESSMAN, FEDERAL PROGRAMS AND CrIV POLITICS (1975); Donald S. Van Meter & Carl
E. Van Horn, The Policy Implementation Process: a Conceptual Framework, 6 ADMIN. & SOC's 445,
446 (1975); CHRISTOPHER C. HooD, THE LIMITS OF ADMINISTRATION (1976); EUGENE
BARDACH, THE IMPLEMENTATION GAME: WHAT HAPPENS AFIER A BILL BECOMES LAw (1977);
EFFECTIVE POLICY IMPLEMENTATION (Daniel Mazmanian & Peter A. Sabatier eds., 1981).
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they dispose of used syringes. These laws, and the police practices
flowing from them, may be understood to be structural factors influ-
encing the health of IDUs. 19 7 There is a growing recognition in public
health that such structural factors are important targets for public
health intervention.' 98
The challenge for research is to further define how substance
abuse policies create health effects, and to suggest how policies and
practices may be changed to improve public health. Recognizing sub-
stance abuse policy and its implementation as significant factors in
health has at least two implications for research.
First, if substance abuse policy is a structural factor in health,
then it is a topic that merits more study from all researchers working
on HIV, MDS, and other diseases linked to drug use. For epidemiolo-
gists, for example, policies and practices at the state and local levels
should be more thoroughly investigated along with the usual individ-
ual demographic and risk factors.' 99 Behavioral research among IDUs
should pay more attention to the effects of policy and policy imple-
mentation on IDUs' behavioral options and choices. Analyses of syr-
inge sharing, for example, that ignore the role of laws and police
behavior are certainly incomplete. The same may be said of health
services research and program evaluation; police attitudes and prac-
tices should be considered as important factors in SEP utilization, for
example. The point is not to ignore non-policy factors, or to make
such factors secondary, but to include policy as one of many impor-
tant factors.
Second, policy data of the sort primarily summarized here-spec-
ifying the kinds of laws that exist on the books across the country-is
important, but incomplete. Law as actually implemented can and
often does differ significantly from the law as written by legislatures or
interpreted by judges. For most people outside the legal system, and
particularly for people like IDUs who are subject to legal intervention,
it is the law on the streets-the law as applied by police officers and
prosecutors-that has the greatest effect on their behavior and daily
197. Kim M. Blankenship et al., Structural Interventions in Public Health, 14 AIDS SI1,
S1 7 (Supp. 1 2000); Esther Sumartojo, Structural Factors in HIV Prevention: Concepts, Exam-
ples, and Implications for Research, 14 AIDS S3, $3-S4 (Supp. 1 2000); Blankenship & Koester,
supra note 170, at 548, 551; see generally Zita Lazzarini & Robert Klitzman, HIV and the Law:
Integrating Law, Policy, and Social Epidemiology, 30J.L., MED. & ETHICS 533, 535 (2002); Scott
Burris et al., Integrating Law and Social Epidemiology, 30 J.L. MED. & ETHICS 510, 511 (2002).
198. See Blankenship et al., supra note 197, at S19.
199. See, e.g., Friedman et al., supra note 93.
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lives.201 Important ethnographic studies of IDUs have begun to docu-
ment and explain these effects, 20 1 but much more needs to be done to
properly delineate the important role of policy in IDU health and
behavior. Ethnography has made and can continue to make an impor-
tant contribution. 2112 As suggested above, however, the implementa-
tion of policy on the streets is a matter for researchers of all kinds.
The challenge for policymakers is to do something to change the
harmful effects of law on health. The scientific evidence, as inter-
preted by most public health professionals, dictates the elimination of
drug policy barriers to safe injection, especially laws and regulations
limiting syringe access. Eleven states have deregulated syringe access
to some extent, and four more have authorized SEPs, but most states
have not acted. The national polling data suggest that public attitudes
are malleable on this issue, but the decisions are made at the state
level. Evidence alone is not decisive in practical policymaking. Leader-
ship and a willingness to abstain from the practice of symbolic politics
are essential ingredients of syringe law reform.
Changing drug possession law, or even instituting law enforce-
ment policies discouraging stops or arrests based on the possession of
a possibly tainted, used syringe, could be even more politically prob-
lematic than syringe law reform. The very suggestion by syringe access
proponents of a change in possession laws may be perceived as ratify-
ing the charge that syringe access generally is merely a political stalk-
ing horse for drug legalization. Despite these considerations, however,
lawmakers in Maryland and the District of Columbia exempted SEP
clients from prosecution for possessing trace amounts of drug in used
syringes, and federal courts in Doe v. Bridgeport Police Department2° ' and
Roe v. City of New York20 4 ruled that state legislatures had intended to
do so when deregulating syringes and authorizing syringe exchange.
The issue of disposal is certainly complex, given the number of
existing regulatory systems it touches and the wide range of social ac-
tors (from individual consumers to waste processors) involved. Unlike
200. See generally PATRICIA EWICK & SUSAN SILBEY, THE COMMON PLACE OF LAw: STORIES
FROM EVERYDAY LIFE (1998); Austin Sarat, "... The Law Is All Over": Power, Resistance and the
Legal Consciousness of the Welfare Poor, 2 YALEJ.L. & HUMAN. 343, 344-345 (1990) (discussing
the effect laws have on everyday life).
201. See, e.g., Blankenship & Koester, supra note 170; Bourgois, supra note 103; Koester,
supra note 103.
202. S.K. Koester, The Context of Risk: Ethnographic Contributions to the Study of Drug Use
and H1V, 143 NIDA RES. MONOGRAPH 202, 213 (1994).
203. 198 F.R.D. 325, 350 (D. Conn. 2001).
204. 232 F. Supp. 2d 240, 257 (S.D. N.Y. 2002).
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syringe access, there is a real price tag: someone has to pay for the
creation and permanent operation of a disposal system. If the lack of a
community disposal system is creating significant costs in injuries,
however, developing a system may be a net benefit. We have suc-
ceeded in developing disposal systems for other commonly used
items, such as batteries and motor oil. Disposal of household sharps
can, with leadership, be rationalized.
Given the challenges, does the research indicate any ways to im-
prove the political fortunes of sterile syringe access and the compre-
hensive approach to drug abuse? There is little written on the political
dynamics of syringe access, and much of that takes the view that drug
and syringe access policy reflect deep structural inequalities of a sort
not likely to be overcome by politics as usual.20 5 From our experience
in drug policy and health, we can suggest some small steps.
Observation of the syringe access debate over time suggests that
syringe access is not in fact the divide across which opponents and
proponents face each other. The debate, that is, is not about the "an-
swer" but the "problem." The problem syringe access proponents seek
to solve is HIV and other blood borne diseases. The problem oppo-
nents are concerned about is drug use and its' implications for the
moral state of society. Syringe access proponents are prepared to take
the risk of compromising drug control in order to prevent disease
(and are reasonably confident that the risk of needle access harming
drug control is very low). People concerned primarily about drug con-
trol are far more averse to any risk that syringe access poses to their
goals. This is reminiscent of the politics that obtained for most of the
first half of the last century in syphilis control. As described by Allen
Brandt, a bitter, decades-long battle over syphilis control policy pitted
those who saw the "problem" as venereal disease (and who therefore
proposed condoms, medical prophylaxis, and education to reduce dis-
ease transmission) against those who saw the "problem" as immoral
sexuality (and who therefore advocated abstinence and even some-
times opposed health measures that would reduce the negative conse-
quences of negative behavior). In this quite analogous context,
advances in STD control depended upon strong leadership from a
charismatic Surgeon General, and coalitions between public health
agencies and private voluntary associations.20 6
205. See Friedman et al., supra note 93, at 793.
206. See ALLAN M. BRANDT, No MAGIC BULLET: A SOCIAL HISTORY OF VENEREAL DISEASE
IN THE UNITED STATES SINCE 1980 (1985).
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Strong public leadership must articulate the high health costs of
drug abuse and how a comprehensive approach including syringe ac-
cess can and does reduce them. It must explicitly address the fear that
a health approach encourages drug use. But it must do more. When
Franklin Roosevelt's Surgeon General, Thomas Paran, first wrote can-
didly about syphilis in Reader's Digest, and spoke openly about it on
national radio, he was attacking a stigma that was making it practically
impossible to undertake widespread public education, screening, and
treatment for STDs. When Surgeon General Koop began to speak out
openly about HIV/AIDS, he was bringing powerful support to an ef-
fort to reduce the stigma of HIV, which has made remarkable pro-
gress in the past twenty years. Success in addressing drug abuse and its
health consequences requires the same sort of anti-stigma campaign.
Until drug users are seen as valuable human beings, and drug abuse
as a complex but treatable disorder, stigma will continue to compli-
cate prevention and act as a brooding omnipresence in legislative
deliberation.2 0 7
Given the challenges, it is important to highlight the many "sec-
ond best" policies that can be helpful intermediate steps towards a
policy of best practices. Retail sales restricted to pharmacies, or to a
limited number of syringes, have been authorized in states where the
votes were not there for complete deregulation. Research suggests
that these measures do improve access. Likewise, SEPs with distribu-
tion caps or other requirements, while not optimal, are valuable. In
states where state-wide support for SEPs has been absent, local govern-
ments have successfully used their inherent health powers to author-
ize exchange.
There are also important steps to be taken that do not involve
legislative change. Our review identified forty-two jurisdictions where
it is clearly or arguably legal for pharmacists to sell syringes to IDUs
without a prescription, and research shows that many pharmacists are
willing to do so. Pharmacists, the gatekeepers for syringe access in the
United States and health professionals with the training to play an
important health promotion role, are a key audience for educational
interventions. A study in Canada concluded:
From a policy perspective, we have found that support from the
federal government, regulatory bodies, and professional associa-
tions may be an important catalyst to pharmacists' participation in
programs [to address substance abuse and its health risks]. Fur-
207. On stigma and the law, see generally S. Burris, Disease Stigma in Public Health Law and
Research, 30J.L. MED. & ETHICS 179 (2002).
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ther, it does not appear to be possible to implement such policies
without professional development and continuing education, and
collaboration with the community.... Movement forward with ex-
panded preventive and harm-reduction strategies by pharmacies
will require careful planning.20 8
The same may be said of police and prosecutors. Mutual mistrust
between health advocates and law enforcement officials is bad for
both sides and the public in the middle. Education on health issues
and the impact of drug abuse health interventions on drug control
can be informative to health and law enforcement professionals alike.
Certainly, the day-to-day success of interventions with drug users can
be enhanced by support and collaboration with law enforcement. Sup-
port from law enforcement is also very helpful, if not indispensable, to
political success.
208. Ted Myers et al., The Role of Policy in Community Pharmacies'Response to Injection-Drug
Use: Results of a Nationwide Canadian Survey, 11 AIDS & PUB. POL'YJ. 78, 87 (1996).
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